WO2013019049A1 - Complex comprising steviol glycosides orlicorice root, and poorly soluble material - Google Patents

Complex comprising steviol glycosides orlicorice root, and poorly soluble material Download PDF

Info

Publication number
WO2013019049A1
WO2013019049A1 PCT/KR2012/006069 KR2012006069W WO2013019049A1 WO 2013019049 A1 WO2013019049 A1 WO 2013019049A1 KR 2012006069 W KR2012006069 W KR 2012006069W WO 2013019049 A1 WO2013019049 A1 WO 2013019049A1
Authority
WO
WIPO (PCT)
Prior art keywords
poorly soluble
licorice
complex
microwave
stevia
Prior art date
Application number
PCT/KR2012/006069
Other languages
French (fr)
Korean (ko)
Inventor
이우송
김영민
노문철
류영배
박수진
정형재
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2013019049A1 publication Critical patent/WO2013019049A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30Artificial sweetening agents
    • A23L27/33Artificial sweetening agents containing sugars or derivatives
    • A23L27/36Terpene glycosides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Definitions

  • the present invention provides a poorly soluble substance-containing complex with increased solubility, a method for preparing the same, a pharmaceutical or food composition comprising the complex, a cosmetic composition or a feed composition comprising the complex, a solubilizer for increasing the solubility of the poorly soluble substance, and A method for solubilizing poorly soluble substances.
  • Solubilization of poorly soluble drugs is an essential technique for administering drugs into the body in oral and injectable form.
  • a method of solubilizing a poorly water-soluble drug firstly, the drug is dissolved in a mixed solvent of a water-miscible organic solvent and water; Second, modifying the structural formula of the drug to form salts of acids or bases that are soluble in water; Third, combining the drug with a third material to form a complex that is soluble in water; Fourth, a method of micellizing a drug in an aqueous solution by adding a surfactant is used (Leon Lachman, "The Theory and Practice of Industrial Pharmacy", Lea & Febiger, Philadelphia, 1986).
  • Alza has developed a technology called nanocrystals, which uses a special mill to break down the particles into nano units and uses new additives to prevent agglomeration between particles. It is applied to soluble drugs and immunosuppressive sirolimus.
  • Glytech is a technology that can promote their absorption by using a taxane-based anticancer agent that is blocked by the P-glycoprotein in combination with a P-glycoprotein inhibitor.
  • Knoll a subsidiary of Abbott, has developed a technology called Meltrex, which significantly improves bioavailability by melting poorly soluble drugs and substrates at high temperatures and then cooling them to amorphize them.
  • SMEDDS self-microemulsifying drug delivery system
  • Paclitaxel which has a market scale of 2 trillion won per year as a single anticancer drug source approved by the US Food and Drug Administration (FDA), is a poorly soluble substance and is not dispersed in distilled water at all. Because of the mixed use has the disadvantage of causing serious side effects to the human body. Therefore, in order to solve this problem, Chitolife Co., Ltd. and Biomedical Polymer Research Team of Sunchon National University prepared advanced chitosan, a non-toxic natural polymer material, and applied it to paclitaxel in 2010, using existing organic solvents. It is much safer than the preparation method, and has a very good redispersibility in distilled water, making the injection formulation much easier to use as an injection.
  • FDA US Food and Drug Administration
  • a method of solubilizing without changing the chemical structure of a drug using a surfactant is widely used as a method for solubilizing various drugs.
  • the surfactant nonionic surfactants such as sorbitan fatty acid ester derivatives (Tween) and polyoxyethylene monoalkyl ether derivatives (BRIJ and MYRJ series) are widely used.
  • Tween sorbitan fatty acid ester derivatives
  • BRIEJ and MYRJ series polyoxyethylene monoalkyl ether derivatives
  • these surfactants are very limited in use due to side effects such as hypersensitivity reactions, there is a disadvantage that the drug is precipitated when left for a relatively long time due to the very low stability of micelles.
  • the present inventors are poorly soluble in a solution to which steviol glycoside or licorice extract is added in order to maximize the solubility of the poorly soluble materials. Not only did solubility increase by dissolving the substance, but also the solubility of the poorly soluble substance was significantly increased as a result of the microwave treatment after dissolving the poorly soluble substance in the solution to which the steviol glycoside or licorice extract was added. By confirming that the present invention was completed, the present invention was completed.
  • Still another object of the present invention is to provide a cosmetic composition comprising the complex.
  • Another object of the present invention is to provide a feed composition comprising the complex.
  • Another object of the present invention relates to a method for producing the composite.
  • Another object of the present invention is to provide the use of the solubilizer.
  • Steviol glycosides included in the complex of the present invention can be used as a solubilizer of a poorly soluble material, the formulation obtained by treating the complex containing the solubilizer with microwave solubility of the poorly soluble material
  • This markedly elevated feature is that it is easy to prepare in oral and injectable formulations, has excellent storage stability, and has excellent drug delivery ability and absorption rate in the body.
  • Figure 1 shows the solubility of curcumin in each condition after dissolving curcumin in a solution containing stevioside at different temperatures.
  • Figure 2 shows the solubility of curcumin in each case by dissolving curcumin in a solution containing steviosides of different concentrations, followed by sonication, a wet sterilizer or a microwave.
  • Figure 3 shows the correlation of four factors by surface response analysis: a, microwave power-stevioside concentration; b, curcumin (KW-100) concentration-microwave power; c, reaction time-microwave power; d, curcumin concentration-stevioside concentration; e, reaction time-stevioside concentration; f, reaction time-curcumin concentration.
  • Figure 4 shows the solubility of curcumin in each case by dissolving curcumin in a solution containing licorice extract of varying concentrations, followed by sonication, wet sterilizer or microwave.
  • the present invention is a steviol glycoside or stevia, or licorice comprising the same; And a poorly soluble material.
  • the present invention provides a pharmaceutical or food composition comprising the complex.
  • the present invention provides a cosmetic composition comprising the complex.
  • the present invention provides a feed composition comprising the complex.
  • the present invention is a steviol glycoside or stevia, or licorice comprising the same, and the first step of mixing a poorly soluble material; And a second step of treating the mixture obtained in the first step with microwaves, thereby providing a method for producing a poorly soluble substance-containing composite having increased solubility.
  • the present invention provides a solubilizer containing licorice as an active ingredient.
  • the present invention provides a method of solubilizing poorly soluble material, comprising mixing licorice with poorly soluble material.
  • the present invention provides the use of licorice in the preparation of a solubilizer.
  • the present invention is a steviol glycoside or stevia, or licorice comprising the same; And a poorly soluble material.
  • the present invention is characterized by using a steviol glycoside as a surfactant that is a solubilizer for poorly soluble substances.
  • the poorly soluble substance when the poorly soluble substance is dissolved in a solution containing steviol glycosides, it was confirmed that the solubility of the poorly soluble substance is significantly increased than when dissolved in water, so that the solubility is increased according to the present invention
  • the complex may comprise stevio glycoside as one component.
  • the term “steviol glycoside” is a compound present in the leaves of Stevia rebaudiana Bertoni, and means a substance that gives a sweet taste.
  • the steviol glycosides are not limited thereto, but the aqueous extract obtained by extracting dried leaves with hot water is concentrated by treatment with an adsorbent resin, and then purified by recrystallization using methyl alcohol or ethyl alcohol, and then dried. And commercially available ones can be used.
  • steviol glycoside is not limited, but stevioside, rebaudioside, rebaudioside A, rebaudioside C, and dulcoside A found in high content in stevia plants
  • rebaudioside B, D, E, F, rubuososide, steviool biosides, steviol monosides and the like can be included, specific chemical structures are as follows.
  • the steviol glycosides of the present invention include enzymatically treated stevia (SWETA), SWETA ML01 containing 50% steviol glycoside, SWETA75 containing 75% steviol glycoside, and the like according to the content and type of steviol glycoside of the chemical structure.
  • SWETA enzymatically treated stevia
  • SWETA ML01 containing 50% steviol glycoside
  • SWETA75 containing 75% steviol glycoside
  • the enzyme treatment stevioside refers to a form in which glucose is added to stevioside (ie, glucosyl stevioside) using a sugar transfer enzyme.
  • the present invention may be prepared using, but not limited to, CGTase (cyclodextringlucanotransferase) or glucose transferase of various microbial origins.
  • steviol glycosides are preferably steviosides.
  • the present invention is to use stevia containing a high content of stevioside, rebaudioside A, rebaudioside C, dulcoside, etc. as a solubilizer for poorly soluble substances. It is characteristic.
  • Stevia is a perennial herbaceous perennial plant with dicotyledonous plants, lanterns, asteraceae, perennial herbaceous perennial herb, inhabiting borderlands and streams and wetlands around South America, Paraguay, Argentina, and Brazil.
  • stevia may be purchased and used commercially, or may be used collected or grown in nature.
  • Stevia is preferably used in the present invention, but is not limited thereto.
  • the stevia is any species of the genus Stevia, such as Stevia rebaudiana, Stevia eupatoria, Stevia ovata, Stevia plummerae, Stevia salicifolia And Stevia serrata.
  • Stevia in the present invention includes the plant itself or a pulverized product, an extract or fraction thereof.
  • stevia may contain about 10 to 95%, preferably about 40 to 85% of steviosides and steviol.
  • the stevia extract can be obtained by extracting with water, a lower alcohol having 1 to 4 carbon atoms (C 1 ⁇ C 4 ) or a mixed solvent thereof. Specifically, about 2 to 10 times the weight of stevia, preferably 2 to 5 times the volume of lower alcohols such as water, ethanol and methanol, preferably ethanol 20 to 50 ° C, preferably 25 to 30 ° C After extraction was obtained by stirring extraction, ultrasonic extraction, continuous extraction 2-3 times by hot water extraction method at 100 °C, filtered through filtrate and the filtrate was removed with a rotary depressurizer, the residue was vacuum lyophilized, hot air drying stevia extract Can be obtained.
  • the stevia extract of the present invention may include any one or more of an extract obtained by the extraction treatment, a dilution or concentrate of the extract, a dried product obtained by drying the extract, and these modifiers or purified products.
  • the present invention is characterized by using licorice as a solubilizer for poorly soluble substances.
  • Licorice is the root of a plant in the genus Glycyrrhiza, which is known to stop coughing, reduce fever, relax the stomach and relieve an emergency.
  • the main component of licorice extract is glycyrrhizinic acid, a white or colorless crystalline powder.
  • Licorice in the present invention includes the plant itself or the pulverized product, extract or fraction thereof. Preferably it may be licorice extract.
  • the licorice extract may be prepared using conventional extraction methods in the art, such as ultrasonic extraction, filtration and reflux extraction.
  • it may be a liquorice dry product obtained by crushing the removed liquorice debris by washing and drying of water, extracted with an alcohol or a mixed solvent of a carbon number of 1 to 4 (C 1 ⁇ C 4) extract, and more preferably It may be an extract extracted with C 1 ⁇ C 4 alcohol, most preferably may be an extract extracted with methanol or ethanol.
  • the extraction solvent is preferably 2 to 20 times the dry weight of licorice.
  • the licorice dry matter is chopped, and then put into an extraction container, a lower alcohol of C 1 to C 4 or a mixed solvent thereof, preferably methanol or ethanol, and allowed to stand at room temperature for a certain period of time, followed by filtration to obtain an alcohol extract. .
  • the extraction is preferably left for 1 week at room temperature, after which it may be further subjected to methods such as concentration or lyophilization.
  • the complex of the present invention may be prepared by purchasing a licorice extract on the market.
  • licorice extract when the poorly soluble substance was dissolved in the solvent containing licorice extract, it was confirmed that the solubility of the poorly soluble substance was significantly increased than when dissolved in water, licorice extract can be used as a solubilizer of poorly soluble substance I found it for the first time.
  • the term “solubilization” refers to a phenomenon in which the solubility of a material that is less soluble in water increases due to the presence of a substance such as a surfactant. Solubilizing oil-soluble vitamins and hormones, such as water-soluble or mixed with fungicides such as phenols to increase the effect, methods for promoting emulsion polymerization are widely applied, etc.
  • a solubilizer steviol glycosides or the like Use stevia, or licorice.
  • the complex of the present invention may be mixed with a steviol glycoside or stevia including the same or licorice with a poorly soluble material to form a complex having a structure in which the poorly soluble material is easily dissolved.
  • steviol glycosides, stevia or licorice containing a range of ratios are not limited, but steviol glycosides or stevia is contained in a concentration of 0.1 to 25% (w / v) (based on solids)
  • licorice is preferably included at a concentration of 0.1 to 30% (w / v) (based on solids).
  • the steviol glycoside or stevia is preferably contained at 1 to 25% (w / v) (based on solids), and licorice is included at a concentration (based on solids) of 0.1 to 25% (w / v). It is desirable to be.
  • the complex of the present invention may be a formulation obtained by treating microwaves.
  • microwave in the present invention is an alternating signal between 300 MHz and 300 GHz in the frequency band or between 1 m and 1 mm in the case of wavelength.
  • a poorly soluble substance when a poorly soluble substance is added to a solution in which stevio glycoside, stevia extract, or licorice extract is mixed, and a homogeneous mixed solution is prepared by sonication, further treatment with ultrasonic treatment is performed.
  • a solubility of the poorly soluble substance by dividing it into the case of microwave treatment and the case of microwave treatment, it was confirmed that the solubilization of the poorly soluble substance was significantly increased when the microwave treatment was performed.
  • the solubility of the poorly soluble material was significantly increased when the microwaves were treated with a wet sterilizer, that is, when it was treated with a high temperature of about 121 ° C. By simply increasing the temperature it can be seen that the solubility is not increased. This is achieved by treating microwaves with a combination of steviol glycosides or licorice that acts as a surfactant and homogenized sparingly soluble material due to sonication, thereby forming a more detailed molecular structure by the instantaneous heat and the wavelength and / or frequency of microwaves alone. Is assumed to be solubilized.
  • the complex is preferably a steviol glycoside or a stevia including the same, or a liquor obtained by mixing the licorice and a poorly soluble substance, followed by sonication. More preferably, steviol glycosides or stevia or licorice comprising the same, and poorly soluble materials are mixed and sonicated, followed by treatment with a wet autoclave, microwave or a mixture thereof, most preferably. Preferably a formulation obtained by treating microwaves.
  • the method of treating the microwave is not limited thereto, but may be reacted to a microwave oven in operation (including general household or synthetic only).
  • the microwave is preferably treated for 1 minute to 20 minutes at 600 W to 800 W in a general household microwave oven, and more preferably, 10 to 20 minutes at 650 W to 750 W, and even more.
  • the treatment is performed at 700 W for 15 minutes.
  • the microwave can be treated for 1 minute to 100 minutes at 50 W to 300 W in a microwave for synthesis only, preferably 1 to 20 minutes to 140 W to 240 W. More preferably, the treatment is performed at 160W to 220W for 6 minutes to 12 minutes, and still more preferably at 180W to 200W for 7 minutes to 10 minutes.
  • the number of microwave treatments is not limited, but is preferably performed two or more times.
  • it can be obtained by adding a step of cooling the complex between each reaction, the formulation can be obtained by the further step of sonicating before reacting in the microwave.
  • the term “poorly soluble substance” refers to a substance having low solubility in water, and specifically, may be a substance having a solubility in water of 50 mg / ml or less.
  • the poorly soluble substance may be, for example, a poorly soluble anticancer agent, an antibacterial agent, a steroid, an anti-inflammatory drug, a sex hormone, an immunosuppressant, an antiviral agent, an anesthetic agent, an antiemetic agent or an antihistamine, and more specifically, paclitaxel, paclitaxel Derivatives, taxotere, adriamycin, teniposide, etoposide, daunomycin, methotrexate, mitomycin C, mitomycin C, carmustine carmustine, busulfan, dactinomycin, lomustine, megestrol acetate, melphalan, mitoxantrone, indomethacin , Etodolac
  • the curcuminoid compound is separated from the turmeric extract, and among them, curcumin having a low solubility (curcumin, solubility of about 11 mg / L) at a concentration of 10 mg / ml, various steviol glycosides It was dissolved in the solution containing.
  • curcumin solubility of about 11 mg / L
  • resveratrol or glucosyl resveratrol was dissolved in a solution containing stevioside, and it was confirmed that 6,200 mg / L resveratrol and 8500 mg / L of glucosyl resveratrol were dissolved. As a result, it was confirmed that the solubility was increased to 9,400 mg / L for resveratrol and 14,300 mg / L for glucosyl resveratrol.
  • the present invention provides a new type of complex which significantly increases the solubility of poorly soluble materials.
  • the present invention relates to a pharmaceutical or food composition comprising the complex described above.
  • the complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
  • the complex is a complex in which the solubility of the poorly soluble substance is significantly increased.
  • the complex When used in a pharmaceutical or food composition, the complex is easy to prepare in oral and injectable form, has excellent storage stability, and delivers drugs. It is characterized by excellent ability and absorption in the body.
  • the therapeutic disease of the pharmaceutical composition of the present invention may vary depending on the type of poorly soluble substance included in the complex, for example, if paclitaxol is included in the complex of the present invention as a poorly soluble substance, the composition may be used for anticancer use. That is, it may be used for the prevention or treatment of cancer, and if curcumin is included in the complex of the present invention as a poorly soluble substance, it may be used for antitumor or anti-inflammatory use, which is a medicinal use of curcumin.
  • composition of the present invention may further comprise a pharmaceutically acceptable carrier.
  • the composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical or food composition is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have either formulation.
  • Examples of the food to which the complex can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
  • the health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage.
  • Natural carbohydrates described above are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin, cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage.
  • the proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage.
  • the proportion of such pulp is not critical, but is generally selected in the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention relates to a method for preventing or treating a disease by administering the complex as described above to a subject.
  • the complex is a complex in which the solubility of the poorly soluble substance is significantly increased, and the disease may vary depending on the type of the poorly soluble substance.
  • the term "individual” means all animals including humans that may be infected with the disease, and by administering the complex described in the present invention to the individual, the disease can be effectively prevented and treated.
  • the route of administration of the complex can be administered via any general route as long as it can reach the target tissue.
  • the complex of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration.
  • the complex may also be administered by any device in which the active agent may migrate to the target cell.
  • the present invention relates to a cosmetic composition comprising the complex described above.
  • the complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
  • the complex is a complex in which the solubility of the poorly soluble substance is significantly increased, and when it is used in a cosmetic composition, it is easy to be formulated into various forms of cosmetics.
  • the cosmetic composition of the present invention may vary depending on the kind of poorly soluble substance included in the complex.
  • the cosmetic composition may be used as a cosmetic composition for whitening.
  • the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, astringent lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as carrier components.
  • animal oil vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc.
  • trakant cellulose derivative
  • polyethylene glycol silicone
  • bentonite silica
  • talc or zinc oxide etc.
  • the formulation of the present invention is a powder or spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide ether.
  • Sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the present invention relates to a feed composition comprising the complex described above.
  • the complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
  • the feed composition also includes the form of a feed additive.
  • the use of the feed composition of the present invention may vary depending on the type of poorly soluble material included in the complex.
  • the poorly soluble substance is curcumin
  • the feed composition may be used as a feed composition to improve influenza virus infection disease and have an anti-influenza effect.
  • the feed may be classified into various types according to nutritional value, main ingredient, distribution, moisture content, blending state and processing type, and the feed may be used as a feed, a rich feed, a supplementary feed, a protein feed, a starch feed, a fat feed or a fiber feed. Possible, but not limited to.
  • the feed composition may additionally contain a carrier that is acceptable to poultry and livestock.
  • the feed can be added as it is or a known carrier, stabilizer and the like, and various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives can be added as necessary.
  • the shape may be in a suitable state such as powder, granules, pellets or suspension.
  • poultry, livestock, and the like can be supplied alone or mixed with feed.
  • the present invention relates to a quasi-drug composition comprising the complex described above.
  • the complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
  • the use of the quasi-drug composition of the present invention may vary depending on the kind of poorly soluble substance included in the complex.
  • the type of quasi-drug is not limited thereto, but may be, for example, a disinfectant cleaner, a disinfectant, a shower foam, a gagreen, a wet tissue, a detergent soap, a shampoo, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.
  • the present invention is a steviol glycoside or stevia, or licorice comprising the same, and the first step of mixing a poorly soluble material; And a second step of subjecting the mixture obtained in the first step to microwaves (microwaves).
  • the steviol glycosides are stevioside, rebaudioside A, rebaudioside C, dulcoside A, which are found in high content in stevia plants, as well as rebaudioside B, D , E, rubisoside, steviol bioside, steviol monoside, SWETA, SWETA ML01, SWETA75 and the like can be included, but is not limited thereto.
  • the poorly soluble substance can be used without limitation as long as it is a substance having low solubility.
  • the present invention is steviol glycosides or stevia, or licorice containing the same, and the poorly soluble substances are mixed in a solvent, or steviol glycosides or stevia, or licorice containing the same, poorly soluble in the solution
  • the material can be added and mixed.
  • the steviol glycoside or stevia in the first step is preferably included in a concentration (solid basis) of 0.1 to 25% (w / v), the licorice is a concentration (solid content of 0.1 to 30% (w / v) It is preferable to include as a reference).
  • the first step is preferably carried out at 60 °C to 80 °C, more preferably at 65 °C to 75 °C, even more preferably at 70 °C.
  • the method of processing the microwave is not limited to this, but may be reacted to a microwave oven in operation (including general household or synthetic only).
  • the microwave is preferably treated for 1 minute to 20 minutes at 600 W to 800 W in a general household microwave oven, and more preferably, 10 to 20 minutes at 650 W to 750 W, even more.
  • the treatment is performed at 700 W for 15 minutes.
  • the microwave can be treated for 1 minute to 100 minutes at 50 W to 300 W in a microwave for synthesis only, preferably 1 to 20 minutes to 140 W to 240 W. More preferably, the treatment is carried out at 160W to 220W for 6 minutes to 12 minutes, and even more preferably at 180W to 200W for 7 minutes to 10 minutes.
  • the number of microwave treatments is not limited, but is preferably performed two or more times.
  • it can be obtained by adding a step of cooling the complex between each reaction, the formulation can be obtained by the further step of sonicating before reacting in the microwave.
  • the solubility of the poorly soluble substance was measured, The solubilization of poorly soluble substances was significantly increased compared to those dissolved in water.
  • the solubility of the poorly soluble substance was measured, and when dissolved in water, after the first step after sonication or wet sterilizer treatment It can be seen that the solubility of the poorly soluble substance was significantly increased.
  • the present invention relates to a solubilizer containing licorice as an active ingredient.
  • licorice comprising the form of the licorice extract of the present invention can be used as a solubilizer, which promotes solubilization of poorly soluble substances.
  • Licorice extract in the solubilizer is not limited thereto, but is preferably included in a concentration of 0.1 to 25% (w / v).
  • the present invention relates to a method of solubilizing poorly soluble materials, comprising mixing licorice with poorly soluble materials.
  • the licorice may be licorice extract.
  • the mixing of the licorice and the poorly soluble substance may be performed as a step of mixing the licorice extract and the poorly soluble substance by adding a poorly soluble substance to the solution containing licorice. Or by mixing licorice extract and poorly soluble material in a solvent.
  • the licorice may increase the solubility of the poorly soluble material and solubilize the poorly soluble material.
  • the method may further comprise treating the microwaves after mixing licorice and the poorly soluble material.
  • the present invention provides the use of licorice in the preparation of solubilizers.
  • the licorice is preferably licorice extract.
  • licorice has a use that can be used to prepare solubilizers of poorly soluble materials.
  • the turmeric used in the present embodiment is generally available in Chinese medicine or on the market, and is dried in the form of dried Root of Curcuma longa Linne and then dried to obtain powder of the present invention to efficiently obtain the extract of the present invention. It was used by grinding. 7.5 L of 100% ethanol (EtOH) was added to 1.6 kg of turmeric, and the mixture was left to stand at room temperature for 5 days, filtered through a filter paper, and concentrated to obtain turmeric ethanol extract (170 g).
  • Example 1-1 170 g of ethanol extract of turmeric obtained in Example 1-1 was added and suspended in 1 L of water. This was placed in a separatory funnel, and fractional extraction using n-hexane and ethyl acetate in order to obtain n-hexane soluble extract (23 g), ethyl acetate soluble extract (85 g) and water soluble extract (34 g).
  • the crude extract was suspended in 1 L of water, mixed with the same amount of ethyl acetate, and fractionated. The procedure was repeated four times to obtain 4 L of ethyl acetate fraction. The ethyl acetate soluble fraction was concentrated under reduced pressure to obtain 80 g of an ethyl acetate soluble extract.
  • the chloroform: methanol 20: 1 fraction in the E. coli ethanol extract, ethyl acetate fraction, and ethyl acetate fraction column chromatography obtained above was analyzed using LC-MS to confirm the resveratrol content.
  • SWETA enzyme treatment stevia
  • curcumin when curcumin was dissolved in a solution containing stevioside, the temperature was set to 30 ° C., 50 ° C., and 70 ° C., and it was confirmed at which temperature the solubilization of curcumin was the highest. As a result, curcumin was dissolved at 110 mg / L at 30 ° C, 170 mg / L at 50 ° C, and 390 mg / L at 70 ° C. That is, it was confirmed that the solubility of curcumin was most increased at 70 °C (Fig. 1).
  • curcumin 10 mg / ml of curcumin is dissolved in stevioside solution and sonicated, followed by sonication, autoclave (121 ° C., 15 psi, 15 minutes), or microwave for 15 minutes in a microwave oven at 700 W. Reaction) were treated for 15 minutes each.
  • the degree of solubilization of curcumin was confirmed under the three conditions, and the results are shown in Table 2 below.
  • solubilized curcumin was optimized using a synthetic-only microwave (CEM's Discover legacy systems model).
  • Basic experiments show four factors: microwave power (50-200 W), stevioside concentration (50-200 mg / L), curcumin concentration (20-200 mg / L), and reaction time 1-10 minutes.
  • microwave power 50-200 W
  • stevioside concentration 50-200 mg / L
  • curcumin concentration 20-200 mg / L
  • reaction time 1-10 minutes. Optimized by surface reaction analysis method at (Table 3).
  • the solubilization of curcumin was excellent at the concentration of licorice extract higher than the low concentration.
  • 10 mg / ml curcumin was dissolved in 0.5, 2, 5, 10% (w / v) licorice extract solution and sonicated, followed by sonication, wet sterilizer (121 ° C., 15 psi, 15 minutes), microwave 15 minutes each.
  • the concentration of licorice extract and the degree of solubilization of curcumin according to the three post-treatments are shown in Table 5 below.
  • Glucosyl resveratrol purchased from Sigma and 20 mg / ml of resveratrol prepared by the method of Example 2 were dissolved for each 0-20% (w / v) stevioside or licorice extract solution, and ultrasonically used at 70 ° C. Treated for 15 minutes. In addition, the microwaves were treated twice each for 15 minutes to quantify the amounts of resveratrol and glucosyl resveratrol solubilized from each solvent using HPLC. The results were compared with the case of only ultrasonic treatment without microwave treatment, and the results are shown in Table 6 below.
  • the amount of resveratrol finally solubilized in the sample to which 20% (w / v) of stevioside was added was 6,200 mg / L, which was 10 mg / L solubilized resveratrol in a solution containing no stevioside It was confirmed that the solubility was significantly increased compared to. In addition, after dissolving resveratrol in a solution containing stevioside, it was confirmed that the amount of solubilized resveratrol was improved to 9,400 mg / L when the microwave treatment.
  • the amount of finally solubilized glucosyl resveratrol in the sample added with 20% (w / v) stevioside was 8,500 mg / L, which was added to 50 mg / L solubilized glucosyl resveratrol in a solution containing no stevioside. Solubility was significantly increased in comparison.
  • microwave treatment of the solution containing steviosides was confirmed that the amount of solubilized resveratrol improved to 14,200 mg / L, which was 71.5% solubilization of the initially added glucosyl resveratrol.
  • the amount of resveratrol finally solubilized in the sample to which 20% (w / v) licorice extract was added was 8,600 mg / L, which was added to 10 mg / L solubilized resveratrol in a solution that did not contain licorice extract. It was confirmed that the solubility was significantly increased. In addition, after dissolving resveratrol in a solution containing licorice extract, when the microwave treatment, the amount of solubilized resveratrol was confirmed to improve to 11,600 mg / L.
  • the amount of finally solubilized glucosyl resveratrol in the sample to which 20% (w / v) licorice extract was added was 10,500 mg / L, which was added to 50 mg / L solubilized glucosyl resveratrol in a solution containing no licorice extract. Solubility was significantly increased in comparison.
  • microwave treatment of the solution containing licorice extract was confirmed that the amount of solubilized resveratrol improved to 17,300 mg / L, which was solubilized 86.5% of the initially added glucosyl resveratrol.
  • the glycyrrhizinic acid purchased from Sigma was dissolved in each 0.1-5% (w / v) stevioside or licorice extract solution at a concentration of 5 mg / ml and treated for 10 minutes using ultrasonic waves at 70 ° C.
  • the amount of glycyrrhizinic acid solubilized from each solvent by treating twice with 15 minutes using microwave was quantified using HPLC.
  • the result of using licorice extract in this manner also showed a gelation reaction when the licorice extract of 0.1-0.5% (w / v) was added, and all of the glycidyl acid initially added with only 1% or more licorice extract was solubilized. It was confirmed to make.
  • Paclitaxol purchased from Sigma was dissolved in each of 0, 5, 10, 20% (w / v) stevioside or licorice extract solution at a concentration of 10 mg / ml, and 10 minutes using ultrasonic waves at 70 ° C.
  • the amount of curcumin solubilized from each solvent was treated and treated twice with 15 minutes using microwaves to quantify using HPLC.
  • solubilization was less than that of stevioside in 10% and 20% (w / v) solutions, but 800 mg / L and microwaves were sonicated when sonicated in 20% (w / v) solutions. It was found that solubilization was improved to 1,900 mg / L when treated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to: a complex with increased solubility of a poorly soluble material, comprising steviol glycosides or stevia containing the same, or licorice root, and a poorly soluble material; a preparation method thereof; a pharmaceutical or food composition containing the complex; a cosmetic or feed composition containing the complex; a solubilizing agent for increasing the solubility of a poorly soluble material; and a method for solubilizing a poorly soluble material. Since the complex of the present invention is remarkably improved in the solubility of a poorly soluble material, the complex can be easily prepared into a dosage form to be administered orally and by injection, has excellent storage stability, and has the effects of remarkable drug delivery ability and absorption rate into the body.

Description

스테비올 배당체 또는 감초, 및 난용성 물질을 포함하는 복합체Complex comprising steviol glycosides or licorice and sparingly soluble substances
본 발명은 가용성이 증가된 난용성 물질 함유 복합체, 이의 제조방법, 상기 복합체를 포함하는 약학 또는 식품 조성물, 상기 복합체를 포함하는 화장료 조성물 또는 사료 조성물, 난용성 물질의 가용성을 증가시키는 가용화제, 및 난용성 물질의 가용화 방법에 관한 것이다.The present invention provides a poorly soluble substance-containing complex with increased solubility, a method for preparing the same, a pharmaceutical or food composition comprising the complex, a cosmetic composition or a feed composition comprising the complex, a solubilizer for increasing the solubility of the poorly soluble substance, and A method for solubilizing poorly soluble substances.
난용성 약물의 가용화는 약물을 경구 및 주사제형으로 체내에 투여하기 위해서 필수적인 기술이다. 물에 난용성인 약물을 가용화시키는 방법으로는 첫째, 수혼화성 유기용매와 물의 혼합 용매에 약물을 용해시키는 방법; 둘째, 약물의 구조식을 변화시켜 물에 용해되는 산 또는 염기의 염 형태로 개량하는 방법; 셋째, 약물을 제3의 물질과 결합시켜 물에 용해되는 복합체(complex)를 형성시키는 방법; 넷째, 계면활성제를 가하여 약물을 수용액 중에 미셀화 시키는 방법 등이 사용되고 있다(Leon Lachman, " The Theory and Practice of Industrial Pharmacy" , Lea & Febiger, Philadelphia, 1986). Solubilization of poorly soluble drugs is an essential technique for administering drugs into the body in oral and injectable form. As a method of solubilizing a poorly water-soluble drug, firstly, the drug is dissolved in a mixed solvent of a water-miscible organic solvent and water; Second, modifying the structural formula of the drug to form salts of acids or bases that are soluble in water; Third, combining the drug with a third material to form a complex that is soluble in water; Fourth, a method of micellizing a drug in an aqueous solution by adding a surfactant is used (Leon Lachman, "The Theory and Practice of Industrial Pharmacy", Lea & Febiger, Philadelphia, 1986).
한편, 미국 및 유럽 등 선진국에서 난용성 약물의 가용화 기술을 개발하는 대표적인 제제개발 전문회사로 Alza, Euland, Knoll, Gatteposse, R.P. Scherer, Ethypharm, Emisphere 등이 있으며, 주로 특화된 가용화 기술제품을 개발하고 있다. 예를 들면, Alza사는 나노입자화 기술 중 특수 분쇄기를 사용하여 입자를 나노단위로 미분화하고 입자 상호간의 응집현상을 막기 위해 새로운 첨가제를 사용하는 것을 특징으로 하는 나노크리스탈이라는 기술을 개발하여 다수의 난용성 약물과 면역억제제인 시로리무스(Sirolimus)에 적용하고 있다. Meanwhile, as a representative formulation development company that develops solubilization technology of poorly soluble drugs in developed countries such as the US and Europe, Alza, Euland, Knoll, Gatteposse, R.P. Scherer, Ethypharm, Emisphere, etc. are mainly developing specialized solubilization technology products. For example, Alza has developed a technology called nanocrystals, which uses a special mill to break down the particles into nano units and uses new additives to prevent agglomeration between particles. It is applied to soluble drugs and immunosuppressive sirolimus.
Euland사는 다양한 가용화 및 흡수개선 제제를 연구하고 있는데, BIORISE이라는 무정형화 기술 및 Glytech 라는 흡수율을 개선시킬 수 있는 기술을 개발하여 제품에 적용하고 있다. 특히 Glytech 기술은 P-당단백질(P-glycoprotein)에 의해 흡수가 차단되는 탁산(Taxane)계 항암제를 P-당단백질 저해제와 병용함으로써 이들의 흡수를 촉진시킬 수 있는 기술이다.Euland is researching various solubilization and absorption improvement agents. It is developing and applying to the product an amorphous technology called BIORISE and a technology to improve the absorption rate called Glytech. In particular, Glytech technology is a technology that can promote their absorption by using a taxane-based anticancer agent that is blocked by the P-glycoprotein in combination with a P-glycoprotein inhibitor.
Abbott의 자회사인 Knoll사는 Meltrex이라는 기술을 개발하였는데, 본 기술의 특징은 난용성 약물과 기재를 고온에서 용융시킨 후 냉각하여 무정형화 시킴으로써 생체이용률을 획기적으로 높일 수 있다.Knoll, a subsidiary of Abbott, has developed a technology called Meltrex, which significantly improves bioavailability by melting poorly soluble drugs and substrates at high temperatures and then cooling them to amorphize them.
프랑스 Gatteffosse사는 SMEDDS (self-microemulsifying drug delivery system)라는 마이크로이멀젼 상태의 미세 용액입자 제어기술을 개발하여 제품에 적용하고 있는데, 이 SMEDDS 기술은 계면활성제, 보조 계면 활성제 및 난용성 약물을 최적의 비율로 혼합, 가용화하여 캅셀에 충진한 것이 특징이다.  Gatteffosse, France, has developed a microemulsion microfluidic particle control technology called SMEDDS (self-microemulsifying drug delivery system) and applied it to the product.The SMEDDS technology provides the optimum ratio of surfactants, co-surfactants and poorly soluble drugs. It is characterized by being mixed and solubilized and filled in a capsule.
국내에서는 한미약품이 마이크로에멀젼 기술을 사용하여 난용성 물질의 용해도를 증가시키고 있으며, 유한양행, 동아제약 등도 면역억제제인 사이클로스포린A, 이트라코나졸 등의 제품에 적용하여 기술수출에 성공한 경험이 있다.In Korea, Hanmi Pharm is using microemulsion technology to increase the solubility of poorly soluble substances, and Yuhan Corp. and Dong-A Pharm have been successful in exporting technology by applying it to products such as cyclosporin A and itraconazole, which are immunosuppressants.
또한, 미국 식품의약국(FDA)의 승인을 받은 단일 항암제 원료로서 연간 2조원의 시장규모를 가진 파클리탁셀(Paclitaxel)은, 난용성 물질로 증류수에 전혀 분산되지 않아 주사제용으로 사용하기 위해서는 또 다른 물질을 혼합하여 사용하기 때문에 인체에 심각한 부작용을 초래하는 단점을 가지고 있다. 따라서 이를 해결하고자, 2010년도에 (주)키토라이프와 순천대학교 생체의료용 고분자연구팀에서 최첨단 나노 기술을 사용해서 독성이 없는 천연고분자 물질인 키토산을 제조하고 이를 파클리탁셀에 적용시킴으로써, 기존의 유기용매를 사용하는 제조방법에 비해 훨씬 안전하고 증류수에서의 재분산 능력이 매우 뛰어나 주사제로서의 이용이 훨씬 용이한 주사제형을 만들었다. In addition, Paclitaxel, which has a market scale of 2 trillion won per year as a single anticancer drug source approved by the US Food and Drug Administration (FDA), is a poorly soluble substance and is not dispersed in distilled water at all. Because of the mixed use has the disadvantage of causing serious side effects to the human body. Therefore, in order to solve this problem, Chitolife Co., Ltd. and Biomedical Polymer Research Team of Sunchon National University prepared advanced chitosan, a non-toxic natural polymer material, and applied it to paclitaxel in 2010, using existing organic solvents. It is much safer than the preparation method, and has a very good redispersibility in distilled water, making the injection formulation much easier to use as an injection.
한편, 난용성 물질의 가용화 방법들 중에서 계면활성제를 사용하여 약물의 화학적인 구조를 변화시키지 않고 가용화하는 방법은 다양한 약물을 가용화할 수 있는 방법으로서 널리 사용되고 있다. 계면활성제로는 소르비탄 지방산 에스테르 유도체(Tween) 및 폴리옥시에틸렌 모노알킬에테르 유도체(BRIJ 및 MYRJ 계열) 등의 비이온성 계면활성제가 널리 사용된다. 그러나 이들 계면활성제는 과민반응 등의 부작용으로 사용이 매우 제한되며, 미셀의 안정성이 매우 낮아서 비교적 장시간 방치할 경우 약물이 석출되는 단점이 있다.Meanwhile, among the solubilization methods of poorly soluble substances, a method of solubilizing without changing the chemical structure of a drug using a surfactant is widely used as a method for solubilizing various drugs. As the surfactant, nonionic surfactants such as sorbitan fatty acid ester derivatives (Tween) and polyoxyethylene monoalkyl ether derivatives (BRIJ and MYRJ series) are widely used. However, these surfactants are very limited in use due to side effects such as hypersensitivity reactions, there is a disadvantage that the drug is precipitated when left for a relatively long time due to the very low stability of micelles.
상기와 같은 난용성 물질의 문제점 및 난용성 물질의 가용화를 위한 기술 개발의 필요성에 따라 본 발명자들은 난용성 물질의 가용성을 최대로 증가시키기 위하여, 스테비올 배당체 또는 감초 추출물이 첨가된 용액에 난용성 물질을 용해시킴으로써, 가용성이 증가되는 것을 확인했을 뿐만 아니라, 스테비올 배당체 또는 감초 추출물이 첨가된 용액에 난용성 물질을 용해시킨 후, 마이크로웨이브를 처리한 결과, 난용성 물질의 가용화도가 현저히 증가되는 것을 확인함으로써, 본 발명을 완성하게 되었다. In accordance with the above problems of poorly soluble materials and the need for the development of technology for solubilizing poorly soluble materials, the present inventors are poorly soluble in a solution to which steviol glycoside or licorice extract is added in order to maximize the solubility of the poorly soluble materials. Not only did solubility increase by dissolving the substance, but also the solubility of the poorly soluble substance was significantly increased as a result of the microwave treatment after dissolving the poorly soluble substance in the solution to which the steviol glycoside or licorice extract was added. By confirming that the present invention was completed, the present invention was completed.
본 발명의 목적은 가용성이 증가된 난용성 물질 함유 복합체를 제공하는 것이다. It is an object of the present invention to provide a poorly soluble material containing composite with increased solubility.
본 발명의 다른 목적은 상기 복합체를 포함하는 체내 흡수율이 증가된 약학 또는 식품 조성물을 제공하는 것이다. It is another object of the present invention to provide a pharmaceutical or food composition having increased absorption in the body including the complex.
본 발명의 또 다른 목적은 상기 복합체를 포함하는 화장료 조성물을 제공하는 것이다. Still another object of the present invention is to provide a cosmetic composition comprising the complex.
본 발명의 또 다른 목적은 상기 복합체를 포함하는 사료 조성물을 제공하는 것이다. Another object of the present invention is to provide a feed composition comprising the complex.
본 발명의 또 다른 목적은 상기 복합체의 제조방법에 관한 것이다. Another object of the present invention relates to a method for producing the composite.
본 발명의 또 다른 목적은 난용성 물질을 가용화시킬 수 있는, 가용화제를 제공하는 것이다. It is another object of the present invention to provide a solubilizer, which can solubilize poorly soluble materials.
본 발명의 또 다른 목적은 난용성 물질을 가용화시키는 방법을 제공하는 것이다. It is another object of the present invention to provide a method for solubilizing poorly soluble materials.
본 발명의 또 다른 목적은 상기 가용화제의 용도를 제공하는 것이다.Another object of the present invention is to provide the use of the solubilizer.
본 발명의 복합체에 포함된 스테비올 배당체, 이를 포함하는 스테비아 또는 감초는 난용성 물질의 가용화제로 사용될 수 있으며, 상기 가용화제를 포함하는 복합체에 마이크로웨이브를 처리하여 수득한 제형은 난용성 물질의 가용성이 현저히 상승되는 특징을 가지는 바, 이는 경구 및 주사제형으로 제조하기 수월하고, 저장 안정성이 뛰어나며, 약물 전달능력 및 체내 흡수율이 뛰어난 효과를 가진다. Steviol glycosides included in the complex of the present invention, stevia or licorice containing the same can be used as a solubilizer of a poorly soluble material, the formulation obtained by treating the complex containing the solubilizer with microwave solubility of the poorly soluble material This markedly elevated feature is that it is easy to prepare in oral and injectable formulations, has excellent storage stability, and has excellent drug delivery ability and absorption rate in the body.
도 1은 온도를 달리하여 커큐민을 스테비오사이드가 포함된 용액에 용해시킨 후, 각 조건에서의 커큐민의 가용화도를 나타낸 것이다. Figure 1 shows the solubility of curcumin in each condition after dissolving curcumin in a solution containing stevioside at different temperatures.
도 2는 커큐민을 농도를 달리한 스테비오사이드가 포함된 용액에 용해시킨 후, 초음파 처리, 습윤 멸균기 또는 마이크로웨이브로 처리하여, 각 경우에서의 커큐민의 가용화도를 나타낸 것이다. Figure 2 shows the solubility of curcumin in each case by dissolving curcumin in a solution containing steviosides of different concentrations, followed by sonication, a wet sterilizer or a microwave.
도 3은 표면반응해석에 의한 4가지 인자의 상관관계: a, 마이크로웨이브 파워-스테비오사이드 농도; b, 커큐민(KW-100)농도-마이크로웨이브 파워; c,반응시간-마이크로웨이브 파워; d, 커큐민 농도-스테비오사이드 농도; e,반응시간-스테비오사이드 농도; f, 반응시간-커큐민 농도에 관한 것이다.Figure 3 shows the correlation of four factors by surface response analysis: a, microwave power-stevioside concentration; b, curcumin (KW-100) concentration-microwave power; c, reaction time-microwave power; d, curcumin concentration-stevioside concentration; e, reaction time-stevioside concentration; f, reaction time-curcumin concentration.
도 4는 커큐민을 농도를 달리한 감초 추출물이 포함된 용액에 용해시킨 후, 초음파 처리, 습윤 멸균기 또는 마이크로웨이브로 처리하여, 각 경우에서의 커큐민의 가용화도를 나타낸 것이다. Figure 4 shows the solubility of curcumin in each case by dissolving curcumin in a solution containing licorice extract of varying concentrations, followed by sonication, wet sterilizer or microwave.
상기 목적을 달성하기 위해, 본 발명은 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초; 및 난용성 물질을 포함하는, 복합체를 제공한다. In order to achieve the above object, the present invention is a steviol glycoside or stevia, or licorice comprising the same; And a poorly soluble material.
다른 양태로서, 본 발명은 상기 복합체를 포함하는 약학 또는 식품 조성물을 제공한다. In another aspect, the present invention provides a pharmaceutical or food composition comprising the complex.
또 다른 양태로서, 본 발명은 상기 복합체를 포함하는 화장료 조성물을 제공한다. As another aspect, the present invention provides a cosmetic composition comprising the complex.
또 다른 양태로서, 본 발명은 상기 복합체를 포함하는 사료 조성물을 제공한다. In another aspect, the present invention provides a feed composition comprising the complex.
또 다른 양태로서, 본 발명은 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초, 및 난용성 물질을 혼합하는 제1단계; 및 상기 제1단계에서 얻어진 혼합물에 마이크로웨이브(microwave)를 처리하는 제2단계를 포함하는, 가용성이 증가된 난용성 물질 함유 복합체의 제조방법을 제공한다. In another aspect, the present invention is a steviol glycoside or stevia, or licorice comprising the same, and the first step of mixing a poorly soluble material; And a second step of treating the mixture obtained in the first step with microwaves, thereby providing a method for producing a poorly soluble substance-containing composite having increased solubility.
또 다른 양태로서, 본 발명은 감초를 유효성분으로 함유하는 가용화제를 제공한다. In another aspect, the present invention provides a solubilizer containing licorice as an active ingredient.
또 다른 양태로서, 본 발명은 감초와 난용성 물질을 혼합하는 단계를 포함하는, 난용성 물질를 가용화시키는 방법을 제공한다. In another aspect, the present invention provides a method of solubilizing poorly soluble material, comprising mixing licorice with poorly soluble material.
또 다른 양태로서, 본 발명은 가용화제의 제조에 있어서, 감초의 용도를 제공한다.In another aspect, the present invention provides the use of licorice in the preparation of a solubilizer.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초; 및 난용성 물질을 포함하는, 복합체에 관한 것이다. The present invention is a steviol glycoside or stevia, or licorice comprising the same; And a poorly soluble material.
본 발명은 스테비올 배당체를 난용성 물질의 가용화제인 계면활성제로 사용하는 것이 특징이다.The present invention is characterized by using a steviol glycoside as a surfactant that is a solubilizer for poorly soluble substances.
본 발명의 실시예에서는 난용성 물질을 스테비올 배당체가 포함된 용액에 용해시켰을 때, 물에 녹인 경우보다 난용성 물질의 가용화도가 현저히 증가되는 것을 확인하였는 바, 본 발명에 따라 가용성이 증가된 복합체는 일 성분으로 스테비오 배당체를 포함할 수 있다. In the embodiment of the present invention, when the poorly soluble substance is dissolved in a solution containing steviol glycosides, it was confirmed that the solubility of the poorly soluble substance is significantly increased than when dissolved in water, so that the solubility is increased according to the present invention The complex may comprise stevio glycoside as one component.
본 발명에서 용어 “스테비올 배당체(steviol glycoside)”는 스테비아(Stevia rebaudiana Bertoni)의 잎에 존재하는 화합물로서, 단맛을 내는 물질을 의미한다. 상기 스테비올 배당체는 이에 제한되지 않으나, 건조 잎을 열수로 추출하여 얻어진 수용성 추출물을 흡착수지로 처리하여 농축한 후, 메틸알콜 또는 에틸알콜을 사용하여 재결정 등의 정제를 거친 후 건조하여 얻어질 수 있으며, 시중에 판매되는 것을 사용할 수 있다. In the present invention, the term “steviol glycoside” is a compound present in the leaves of Stevia rebaudiana Bertoni, and means a substance that gives a sweet taste. The steviol glycosides are not limited thereto, but the aqueous extract obtained by extracting dried leaves with hot water is concentrated by treatment with an adsorbent resin, and then purified by recrystallization using methyl alcohol or ethyl alcohol, and then dried. And commercially available ones can be used.
스테비올 배당체의 종류는 한정되지 않으나, 스테비아 식물에서 높은 함량으로 발견되는 스테비오사이드(stevioside), 레바우디오사이드(rebaudioside), 레바우디오사이드 A, 레바우디오사이드 C, 둘코사이드(dulcoside) A 뿐만 아니라, 레바우디오사이드 B, D, E, F, 루부소사이드(rubuososide), 스테비올 비오사이드, 스테비올 모노사이드 등이 포함될 수 있으며, 구체적인 화학구조는 하기와 같다.The type of steviol glycoside is not limited, but stevioside, rebaudioside, rebaudioside A, rebaudioside C, and dulcoside A found in high content in stevia plants In addition, rebaudioside B, D, E, F, rubuososide, steviool biosides, steviol monosides and the like can be included, specific chemical structures are as follows.
화학식 1
Figure PCTKR2012006069-appb-C000001
Formula 1
Figure PCTKR2012006069-appb-C000001
Figure PCTKR2012006069-appb-I000001
Figure PCTKR2012006069-appb-I000001
또한, 본 발명의 스테비올 배당체에는 상기 화학구조의 스테비올 배당체 함량과 종류에 따라 효소처리 스테비아(SWETA), 스테비올 배당체 50%을 함유한 SWETA ML01, 스테비올 배당체 75%을 함유한 SWETA75 등이 포함될 수 있다In addition, the steviol glycosides of the present invention include enzymatically treated stevia (SWETA), SWETA ML01 containing 50% steviol glycoside, SWETA75 containing 75% steviol glycoside, and the like according to the content and type of steviol glycoside of the chemical structure. Can be included
상기 효소처리 스테비오사이드는 당전이 효소를 사용하여 스테비오사이드에 포도당이 부가된 형태(즉, 글루코실 스테비오사이드)를 의미한다. 이에 제한되지는 않으나, CGTase(사이클로덱스트린글루카노트랜스퍼라제) 또는 여러 미생물 기원의 글루코스 전이효소를 이용하여 제조될 수 있다. The enzyme treatment stevioside refers to a form in which glucose is added to stevioside (ie, glucosyl stevioside) using a sugar transfer enzyme. The present invention may be prepared using, but not limited to, CGTase (cyclodextringlucanotransferase) or glucose transferase of various microbial origins.
본 발명에서 스테비올 배당체는 스테비오사이드가 바람직하다. In the present invention, steviol glycosides are preferably steviosides.
또한, 본 발명은 스테비오사이드(stevioside), 레바우디오사이드(rebaudioside) A, 레바우디오사이드 C, 둘코사이드(dulcoside) 등을 높은 함량으로 포함하고 있는 스테비아를 난용성 물질의 가용제로 사용하는 것이 특징이다. In addition, the present invention is to use stevia containing a high content of stevioside, rebaudioside A, rebaudioside C, dulcoside, etc. as a solubilizer for poorly soluble substances. It is characteristic.
스테비아는 쌍떡잎식물 초롱꽃목 국화과 숙근(宿根) 다년초 여러해살이풀로서 남미 파라과이, 아르헨티나, 브라질 등의 국경산간지 하천, 습지대주변에 서식하며 허브차, 음료, 한약조제, 천연감미료, 당뇨, 다이어트, 건강보조식품 등에 사용한다. Stevia is a perennial herbaceous perennial plant with dicotyledonous plants, lanterns, asteraceae, perennial herbaceous perennial herb, inhabiting borderlands and streams and wetlands around South America, Paraguay, Argentina, and Brazil. Herbal tea, beverages, herbal preparations, natural sweeteners, diabetes, diet, and health supplements. Used for food.
본 발명에서 스테비아는 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있다.In the present invention, stevia may be purchased and used commercially, or may be used collected or grown in nature.
본 발명에서 스테비아는 잎 부위를 사용하는 것이 바람직하나, 이에 제한되는 것은 아니다. Stevia is preferably used in the present invention, but is not limited thereto.
상기 스테비아는 스테비아 속의 임의의 종, 예컨대 스테비아 레바우디아나(Stevia rebaudiana), 스테비아 유파토리아(Stevia eupatoria), 스테비아 오바타(Stevia ovata), 스테비아 플루머라에(Stevia plummerae), 스테비아 살리시폴리아(Stevia salicifolia) 및 스테비아 세라타(Stevia serrata)일 수 있다.The stevia is any species of the genus Stevia, such as Stevia rebaudiana, Stevia eupatoria, Stevia ovata, Stevia plummerae, Stevia salicifolia And Stevia serrata.
본 발명에서 스테비아는 식물 그 자체 또는 분쇄물, 이의 추출물 또는 분획물을 포함한다.  Stevia in the present invention includes the plant itself or a pulverized product, an extract or fraction thereof.
일반적으로, 스테비아는 약 10 내지 95 %, 바람직하게는 약 40 내지 85 %의 스테비오사이드 및 스테비올을 함유할 수 있다.In general, stevia may contain about 10 to 95%, preferably about 40 to 85% of steviosides and steviol.
본 발명에서, 스테비아 추출물은 물, 탄소수 1 내지 4(C1~C4)의 저급알콜 또는 이들의 혼합용매로 추출하여 얻을 수 있다. 구체적으로, 스테비아 중량의 약 2~10배, 바람직하게는 2~5배의 부피의 물, 에탄올, 메탄올과 같은 저급 알코올로, 바람직하게는 에탄올로 20~50℃, 바람직하게는 25~30℃에서 교반 추출, 초음파 추출, 100℃에서 열수 추출방법으로 2~3회 연속 추출하여 수득한 후, 여지로 여과하고 여과액을 회전식 감압 농축기로 제거한 후 잔사를 진공 동결건조, 열풍건조를 통하여 스테비아 추출물을 얻을 수 있다. In the present invention, the stevia extract can be obtained by extracting with water, a lower alcohol having 1 to 4 carbon atoms (C 1 ~ C 4 ) or a mixed solvent thereof. Specifically, about 2 to 10 times the weight of stevia, preferably 2 to 5 times the volume of lower alcohols such as water, ethanol and methanol, preferably ethanol 20 to 50 ° C, preferably 25 to 30 ° C After extraction was obtained by stirring extraction, ultrasonic extraction, continuous extraction 2-3 times by hot water extraction method at 100 ℃, filtered through filtrate and the filtrate was removed with a rotary depressurizer, the residue was vacuum lyophilized, hot air drying stevia extract Can be obtained.
또한, 본 발명의 상기 스테비아 추출물은 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물 및 이들 조정제물 또는 정제물 중 어느 하나 이상을 포함할 수 있다.In addition, the stevia extract of the present invention may include any one or more of an extract obtained by the extraction treatment, a dilution or concentrate of the extract, a dried product obtained by drying the extract, and these modifiers or purified products.
또한, 본 발명은 감초를 난용성 물질의 가용화제로 사용하는 것이 특징이다. 감초는 글리시리자(Glycyrrhiza)속 식물의 뿌리로서, 기침을 멈추고, 열을 내리고, 위를 편안하게 하며, 긴급한 상황을 완화시켜 주는 것으로 알려져 있다. 감초 추출물의 주요 성분은 백색 또는 무색의 결정성 분말인 글리실리진산(glycyrrhizinic acid)이다. In addition, the present invention is characterized by using licorice as a solubilizer for poorly soluble substances. Licorice is the root of a plant in the genus Glycyrrhiza, which is known to stop coughing, reduce fever, relax the stomach and relieve an emergency. The main component of licorice extract is glycyrrhizinic acid, a white or colorless crystalline powder.
본 발명에서 감초는 식물 그 자체 또는 분쇄물, 이의 추출물 또는 분획물을 포함한다. 바람직하게는 감초 추출물일 수 있다.  Licorice in the present invention includes the plant itself or the pulverized product, extract or fraction thereof. Preferably it may be licorice extract.
상기 감초 추출물을 제조하는 방법은 초음파 추출법, 여과법 및 환류추출법 등 당업계의 통상적인 추출방법을 사용할 수 있다. 바람직하게는 세척 및 건조로 이물질이 제거된 감초를 분쇄하여 얻은 감초 건조물을 물, 탄소수 1 내지 4(C1~C4)의 알코올 또는 이들의 혼합용매로 추출한 추출물일 수 있으며, 보다 바람직하게는 C1~C4의 알코올로 추출한 추출물일 수 있고, 가장 바람직하게는 메탄올 또는 에탄올로 추출한 추출물일 수 있다. 이때, 추출용매는 감초의 건조중량의 2 ~ 20 배로 하는 것이 바람직하다. 일례로 감초 건조물을 세절한 후 추출용기에 넣고 C1~C4의 저급 알코올 또는 이들의 혼합용매, 바람직하게는 메탄올 또는 에탄올을 넣고 일정기간 상온에서 방치한 다음, 여과하여 알코올 추출물을 얻을 수 있다. 이때, 추출은 상온에서 1주 동안 방치하는 것이 바람직하며, 이후에 농축 또는 동결건조 등의 방법을 추가적으로 거칠 수 있다. 또는 시중에 판매되고 있는 감초 추출물을 구입하여 이를 일성분으로 하는 본 발명의 복합체를 제조할 수 있다. The licorice extract may be prepared using conventional extraction methods in the art, such as ultrasonic extraction, filtration and reflux extraction. Preferably it may be a liquorice dry product obtained by crushing the removed liquorice debris by washing and drying of water, extracted with an alcohol or a mixed solvent of a carbon number of 1 to 4 (C 1 ~ C 4) extract, and more preferably It may be an extract extracted with C 1 ~ C 4 alcohol, most preferably may be an extract extracted with methanol or ethanol. At this time, the extraction solvent is preferably 2 to 20 times the dry weight of licorice. For example, the licorice dry matter is chopped, and then put into an extraction container, a lower alcohol of C 1 to C 4 or a mixed solvent thereof, preferably methanol or ethanol, and allowed to stand at room temperature for a certain period of time, followed by filtration to obtain an alcohol extract. . At this time, the extraction is preferably left for 1 week at room temperature, after which it may be further subjected to methods such as concentration or lyophilization. Alternatively, the complex of the present invention may be prepared by purchasing a licorice extract on the market.
본 발명의 실시예에서는 감초 추출물이 포함된 용매에 난용성 물질을 용해한 경우, 물에 용해한 경우보다 난용성 물질의 가용성이 현저히 증가되었음을 확인하였는 바, 감초 추출물을 난용성 물질의 가용화제로 사용할 수 있음을 처음으로 발견해내었다. In the embodiment of the present invention, when the poorly soluble substance was dissolved in the solvent containing licorice extract, it was confirmed that the solubility of the poorly soluble substance was significantly increased than when dissolved in water, licorice extract can be used as a solubilizer of poorly soluble substance I found it for the first time.
본 발명에서 용어, “가용화”란, 계면활성제와 같은 물질의 존재에 의해 물에 잘 녹지 않는 물질의 용해도가 증가하는 현상을 의미한다. 유용성 비타민이나 호르몬 등을 가용화하여 수용성으로 바꾸거나 페놀류 등 살균제와 혼용하여 효과를 증가시키는 방법, 에멀션 중합을 촉진하는 방법 등이 널리 응용되고 있는데, 본 발명에서는 가용화제로서, 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초를 사용한다. As used herein, the term “solubilization” refers to a phenomenon in which the solubility of a material that is less soluble in water increases due to the presence of a substance such as a surfactant. Solubilizing oil-soluble vitamins and hormones, such as water-soluble or mixed with fungicides such as phenols to increase the effect, methods for promoting emulsion polymerization are widely applied, etc. In the present invention, as a solubilizer, steviol glycosides or the like Use stevia, or licorice.
본 발명의 복합체는 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초가 난용성 물질과 혼합되어, 난용성 물질이 용해되기 쉬운 구조를 가지는 복합체를 형성할 수 있다. The complex of the present invention may be mixed with a steviol glycoside or stevia including the same or licorice with a poorly soluble material to form a complex having a structure in which the poorly soluble material is easily dissolved.
또한, 본 발명의 복합체에서는 스테비올 배당체, 스테비아 또는 감초가 포함되는 비율의 범위는 제한이 없으나, 스테비올 배당체 또는 스테비아가 0.1 내지 25%(w/v)의 농도(고형분 기준)로 포함되는 것이 바람직하며, 감초는 0.1 내지 30%(w/v)의 농도(고형분 기준)로 포함되는 것이 바람직하다. In addition, in the complex of the present invention, steviol glycosides, stevia or licorice containing a range of ratios are not limited, but steviol glycosides or stevia is contained in a concentration of 0.1 to 25% (w / v) (based on solids) Preferably, licorice is preferably included at a concentration of 0.1 to 30% (w / v) (based on solids).
보다 바람직하게는, 스테비올 배당체 또는 스테비아가 1 내지 25%(w/v)(고형분 기준)로 포함되는 것이 바람직하며, 감초는 0.1 내지 25%(w/v)의 농도(고형분 기준)로 포함되는 것이 바람직하다. More preferably, the steviol glycoside or stevia is preferably contained at 1 to 25% (w / v) (based on solids), and licorice is included at a concentration (based on solids) of 0.1 to 25% (w / v). It is desirable to be.
또한, 본 발명의 복합체는 마이크로웨이브를 처리하여 얻은 제형일 수 있다.In addition, the complex of the present invention may be a formulation obtained by treating microwaves.
본 발명에서 용어 "마이크로웨이브"란, 주파수 대역이 300MHz 에서 300GHz 사이 또는 파장의 경우 1m에서 1mm 사이의 교류 신호이다. The term "microwave" in the present invention is an alternating signal between 300 MHz and 300 GHz in the frequency band or between 1 m and 1 mm in the case of wavelength.
본 발명의 실시예에서는 스테비오 배당체, 스테비아 추출물 또는 감초 추출물이 혼합된 용액에 난용성 물질을 첨가하고, 초음파 처리로 균질한 혼합액을 준비한 후, 초음파 처리를 추가로 더 처리하는 경우, 습윤 멸균기를 처리하는 경우, 및 마이크로웨이브(microwave)를 처리하는 경우로 나누어 난용성 물질의 가용화도를 측정한 결과, 마이크로웨이브를 처리한 경우가 다른 경우보다 난용성 물질의 가용화를 현저히 증가시키는 것을 확인하였다. In an embodiment of the present invention, when a poorly soluble substance is added to a solution in which stevio glycoside, stevia extract, or licorice extract is mixed, and a homogeneous mixed solution is prepared by sonication, further treatment with ultrasonic treatment is performed. As a result of measuring the solubility of the poorly soluble substance by dividing it into the case of microwave treatment and the case of microwave treatment, it was confirmed that the solubilization of the poorly soluble substance was significantly increased when the microwave treatment was performed.
본 발명의 가용화제와 난용성 물질을 혼합한 후, 습윤 멸균기 즉, 약 121℃의 고온으로 이를 처리한 경우보다 마이크로웨이브를 처리한 경우에 난용성 물질의 가용성이 현저히 증가하였는 바, 마이크로웨이브 처리에 의해 단순히 온도가 증가되어 가용화도가 증가된 것이 아님을 알 수 있다. 이는 초음파 처리로 인해 균질화된 난용성 물질과 계면활성제 역할을 해주는 스테비올 배당체 또는 감초와의 결합에 마이크로웨이브를 처리함으로써 순간적인 열과 마이크로웨이브만의 파장 및/또는 주파수에 의해 더욱 세밀한 분자구조를 형성하여 가용화되는 것으로 추정된다.After mixing the solubilizer and the poorly soluble material of the present invention, the solubility of the poorly soluble material was significantly increased when the microwaves were treated with a wet sterilizer, that is, when it was treated with a high temperature of about 121 ° C. By simply increasing the temperature it can be seen that the solubility is not increased. This is achieved by treating microwaves with a combination of steviol glycosides or licorice that acts as a surfactant and homogenized sparingly soluble material due to sonication, thereby forming a more detailed molecular structure by the instantaneous heat and the wavelength and / or frequency of microwaves alone. Is assumed to be solubilized.
상기 실험 내용을 바탕으로, 본 발명에서 상기 복합체는 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초 및 난용성 물질을 혼합시킨 후, 초음파 처리하여 얻어지는 제형이 바람직하다. 보다 바람직하게는, 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초, 및 난용성 물질 혼합시키고 초음파 처리한 후, 습윤 멸균기(auto clave), 마이크로웨이브(microwave) 또는 이들을 혼합하여 처리하는 것이며, 가장 바람직하게는 마이크로웨이브를 처리하여 얻어지는 제형이다. Based on the above test results, in the present invention, the complex is preferably a steviol glycoside or a stevia including the same, or a liquor obtained by mixing the licorice and a poorly soluble substance, followed by sonication. More preferably, steviol glycosides or stevia or licorice comprising the same, and poorly soluble materials are mixed and sonicated, followed by treatment with a wet autoclave, microwave or a mixture thereof, most preferably. Preferably a formulation obtained by treating microwaves.
상기 마이크로웨이브를 처리하는 방법은 이에 제한되지는 않으나, 작동중인 전자레인지(microwave oven; 일반 가정용 또는 합성 전용 모두 포함)에 반응시킬 수 있다. 또한, 상기 마이크로웨이브는 일반 가정용 전자레인지에서 600 W 내지 800 W로 1분 내지 20분간 처리하는 것이 바람직하며, 보다 바람직하게는, 650 W 내지 750 W로 10분 내지 20분간 처리하는 것이며, 보다 더 바람직하게는, 700W로 15분간 처리하는 것이다. 또한, 상기 마이크로웨이브는 합성 전용 전자레인지에서 50 W 내지 300 W로 1분 내지 100분간 처리될 수 있으며, 바람직하게는 140 W 내지 240 W로 1분 내지 20분간 처리하는 것이다. 보다 바람직하게는, 160W 내지 220 W로 6분 내지 12분간 처리하는 것이며, 보다 더 바람직하게는, 180 W 내지 200 W로 7분 내지 10분간 처리하는 것이다. 합성 전용 전자레인지를 사용한 경우에는 난용성 물질의 가용화도가 가정용 전자레인지를 사용한 경우보다 증진되었으며, 구체적으로, 커큐민을 10 mg/ml의 농도로 스테비오사이드를 포함하는 용액에 용해시켰을 때, 약 17,000 mg/L의 농도로 커큐민이 가용화되는 것을 확인할 수 있었다(실시예 3). The method of treating the microwave is not limited thereto, but may be reacted to a microwave oven in operation (including general household or synthetic only). In addition, the microwave is preferably treated for 1 minute to 20 minutes at 600 W to 800 W in a general household microwave oven, and more preferably, 10 to 20 minutes at 650 W to 750 W, and even more. Preferably, the treatment is performed at 700 W for 15 minutes. In addition, the microwave can be treated for 1 minute to 100 minutes at 50 W to 300 W in a microwave for synthesis only, preferably 1 to 20 minutes to 140 W to 240 W. More preferably, the treatment is performed at 160W to 220W for 6 minutes to 12 minutes, and still more preferably at 180W to 200W for 7 minutes to 10 minutes. The solubilization of poorly soluble substances was enhanced in the case of using a synthetic microwave, in particular, when curcumin was dissolved in a solution containing stevioside at a concentration of 10 mg / ml, about 17,000. It was confirmed that curcumin is solubilized at a concentration of mg / L (Example 3).
마이크로웨이브 처리 횟수는 제한이 없으나, 2회 이상 수행하는 것이 바람직하다. 또한, 각 반응 사이에 복합체를 식히는 단계를 추가하여 얻어질 수 있으며, 상기 제형은 전자레인지에 반응시키기 전에 초음파 처리하는 단계를 추가로 하여 얻어질 수 있다. The number of microwave treatments is not limited, but is preferably performed two or more times. In addition, it can be obtained by adding a step of cooling the complex between each reaction, the formulation can be obtained by the further step of sonicating before reacting in the microwave.
본 발명에서 “난용성 물질”이란, 물에 대한 용해도가 낮은 물질을 의미하며, 구체적으로는 물에 대한 용해도가 50 ㎎/㎖ 이하인 물질일 수 있다. 난용성 물질은 예를 들어, 난용성 항암제, 항균제, 스테로이드류, 소염진통제, 성호르몬, 면역 억제제, 항바이러스제, 마취제, 항구토제 또는 항히스타민제 등일 수 있으며, 보다 구체적으로는 파클리탁셀(paclitaxel), 파클리탁셀 유도체, 탁소티어(taxotere), 아드리아마이신(adriamycin), 테니포사이드(teniposide), 에토포사이드(etoposide), 다우노마이신(daunomycin), 메토트렉세이트(methotrexate), 미토마이신 C(mitomycin C), 카르무스틴(carmustine), 부설판(busulfan), 닥티노마이신(dactinomycin), 로무스틴(lomustine), 메게스트롤 아세테이트(megestrol acetate), 멜파란(melphalan), 마이토잔트론(mitoxantrone), 인도메타신(indomethacin), 에토도락(etodolac), 이부프로펜(ibuprofen), 캄토테신(camptothecin), 토포테칸(topotecan), 아스피린(aspirin), 피록시캄(piroxicam), 시메티딘(cimetidine), 에스트로겐(estrogen), 프레드니솔론(prednisolone), 코티손(cortisone), 하이드로코티손(hydrocortisone), 디플로라손(diflorasone), 페네스테린(phenesterine), 다우노루비신(daunorubicin), 미토탄(mitotane), 비사딘(visadine), 할로니트로소레아류(halonitrosouureas), 앤트로사이클린류(antrocyclines), 엘립티신(ellipticine), 디아제팜(diazepam), 오메프라졸(omeprazole), 메톡시플루오란(methoxyfluorane), 이소플루오란(isofluorane), 엔플루오란(enfluorane), 할로탄(halothane), 벤조카인(benzocaine), 단트롤린(dantrolene), 바르비투레이트(barbiturates), 사이클로스포린 A(cyclosporin A), 아자티오프린(azathioprine), 암포테리신 B(amphotericin B), 나이스타틴(nystatine), 이트라코나졸(itraconazole), 비페닐 디메칠 디카르복실레이트(biphenyl dimethyl dicarboxylate(BDD)), 이데베논(idebenone), 피포술판(piposulfan), 다나졸(danazole), 헤모글로빈(hemoglobin), 커큐미노이드계(curcuminoid) 화합물, 레스베라트롤(resveratrol), 글리실리진산(glycyrrhizinic acid) 및 그의 유도체로부터 구성된 군으로부터 선택되는 것이며, 이에 제한되지는 않는다. 상기 커큐미노이드계 화합물로는, 커큐민(curcumin), 커큐데메톡시커큐민 (Demethoxycurcumin), 비스데메톡시커큐민 (Bisdemethoxycurcumin)을 포함한다. As used herein, the term “poorly soluble substance” refers to a substance having low solubility in water, and specifically, may be a substance having a solubility in water of 50 mg / ml or less. The poorly soluble substance may be, for example, a poorly soluble anticancer agent, an antibacterial agent, a steroid, an anti-inflammatory drug, a sex hormone, an immunosuppressant, an antiviral agent, an anesthetic agent, an antiemetic agent or an antihistamine, and more specifically, paclitaxel, paclitaxel Derivatives, taxotere, adriamycin, teniposide, etoposide, daunomycin, methotrexate, mitomycin C, mitomycin C, carmustine carmustine, busulfan, dactinomycin, lomustine, megestrol acetate, melphalan, mitoxantrone, indomethacin , Etodolac, ibuprofen, camptothecin, camptothecin, topotecan, aspirin, pyroxicam, cimetidine, estrogen, estrogen Prednisolone, cortisone, hydrocortisone, diflorasone, phenesterine, daunorubicin, mitotane, visadine, halo Nitrosoreas, anthrocyclines, elliptices, diazepam, omeprazole, methoxyfluorane, isofluorane, enfluoran (enfluorane, halotane, benzocaine, dantrolene, barbiturates, cyclosporin A, azathioprine, amphotericin B (amphotericin) B), nystatine, itraconazole, biphenyl dimethyl dicarboxylate (BDD), idebenone, piposulfan, danazole, hemoglobin ( hemoglobin), curcuminoid compound , Resveratrol (resveratrol), silico-glycidyl alginic acid will be selected from (glycyrrhizinic acid) and its derivatives from the group consisting of, but are not limited to. The curcuminoid-based compound includes curcumin, curcudemethoxycurcumin, and bisdemethoxycurcumin.
본 발명의 일 실시예에서는 울금 추출물로부터 커큐미노이드계 화합물을 분리하여, 그 중에서 용해도가 낮은 커큐민(curcumin, 용해도는 약 11 mg/L)을 10 mg/ml의 농도로 여러 종류의 스테비올 배당체가 포함된 용액에 용해시켰다. 그 결과, 물에서 거의 녹지 않았던 커큐민이 스테비올 배당체가 포함된 용액에서 가용화도가 증가되었으며, 그 중에서 스테비오사이드가 포함된 용액에서 가용화도는 물 대비 약 318배 증가되었다. 이에 일반 가정용 마이크로웨이브를 추가로 처리해 준 결과, 커큐민이 3,500 mg/L 까지 용해됨을 확인하였다(실시예 3). 또한, 감초 추출물이 포함된 용액에 커큐민을 10 mg/ml의 농도로 용해시킨 후, 일반 가정용 마이크로웨이브를 처리해준 결과, 커큐민은 5,100 mg/L 까지 가용화됨을 확인하였다(실시예 4). 또한, 합성 전용 마이크로웨이브를 이용하여 마이크로웨이브를 약 189 W, 약 8.9분을 처리한 결과, 커큐민의 가용화는 17,000 mg/L까지 가능하였으며(실시예 3), 지금까지 알려진 커큐민의 최고의 가용화 정도를 나타냈으며, 물에서의 가용화 정도와 비교하면 약 1,545배 향상된 결과를 얻을 수 있었다. In an embodiment of the present invention, the curcuminoid compound is separated from the turmeric extract, and among them, curcumin having a low solubility (curcumin, solubility of about 11 mg / L) at a concentration of 10 mg / ml, various steviol glycosides It was dissolved in the solution containing. As a result, the solubilization of curcumin, which was hardly soluble in water, increased in the solution containing steviol glycosides, and the solubility in the solution containing stevioside was increased about 318 times compared to water. As a result of further treatment with the general household microwave, it was confirmed that curcumin dissolved to 3,500 mg / L (Example 3). In addition, after dissolving curcumin at a concentration of 10 mg / ml in a solution containing licorice extract, as a result of treating the general domestic microwave, it was confirmed that the curcumin is solubilized to 5,100 mg / L (Example 4). In addition, as a result of treating microwaves using about 189 W and about 8.9 minutes using a synthetic-only microwave, the solubilization of curcumin was possible up to 17,000 mg / L (Example 3). As compared with the degree of solubilization in water, about 1,545 times improved results were obtained.
본 발명의 다른 실시예에서는, 레스베라트롤 또는 글루코실 레스베라트롤 10 mg을 스테비오사이드가 포함된 용액에 용해시켜, 레스베라트롤 6,200 mg/L, 글루코실 레스베라트롤 8500 mg/L 이 용해됨을 확인하였으며, 이에 가정용 마이크로웨이브를 처리해준 결과, 레스베라트롤이 9,400 mg/L, 글루코실 레스베라트롤이 14,300 mg/L까지 가용화도가 증가되는 것을 확인하였다. 또한, 감초 추출물이 포함된 용액에 용해시켰을 때, 레스베라트롤이 8,600 mg/L, 글루코실 레스베라트롤이 10,500 mg/L이 용해되었으며, 이에 가정용 마이크로웨이브를 처리해준 결과, 레스베라트롤이 11,600 mg/L, 글루코실 레스베라트롤이 17,300 mg/L까지 가용화도가 증가되는 것을 확인하였다. 상기의 결과는 아무것도 처리하지 않은 군에서 레스베라트롤이 10 mg/L, 글루코실 레스베라트롤이 50 mg/L 이 용해된 것에 비해 가용화도가 현저히 증가된 결과이다(실시예 5). In another embodiment of the present invention, 10 mg of resveratrol or glucosyl resveratrol was dissolved in a solution containing stevioside, and it was confirmed that 6,200 mg / L resveratrol and 8500 mg / L of glucosyl resveratrol were dissolved. As a result, it was confirmed that the solubility was increased to 9,400 mg / L for resveratrol and 14,300 mg / L for glucosyl resveratrol. In addition, when dissolved in a solution containing licorice extract, resveratrol was dissolved 8,600 mg / L, glucosyl resveratrol 10,500 mg / L, resveratrol 11,600 mg / L, glucosyl Resveratrol was confirmed to increase the solubility to 17,300 mg / L. The above results indicate that solubility was significantly increased in the group treated with nothing compared to 10 mg / L of resveratrol and 50 mg / L of glucosyl resveratrol (Example 5).
본 발명의 또 다른 실시예에서는 난용성 물질로 알려진 글리시리진산과 파크리탁솔을 스테비오사이드 또는 감초 추출물이 포함된 용액에 녹인 후, 마이크로웨이브를 처리해 준 결과, 적은 농도의 스테비오사이드 또는 감초 추출물에서도 겔화 반응이 빠르게 진행되었으며, 이들의 가용화도도 현저히 증가됨을 확인할 수 있었다(실시예 6, 7)In another embodiment of the present invention, after dissolving glycyrrhizinic acid and paclitaxol, which are known as poorly soluble substances, in a solution containing stevioside or licorice extract, the result of microwave treatment results in gelation reaction in a stevioside or licorice extract of small concentration. This progressed rapidly, and it was confirmed that their solubility was also significantly increased (Examples 6 and 7).
요컨대, 본 발명은 난용성 물질의 가용성을 현저히 증가시키는 새로운 형태의 복합체를 제공하는 것이다. In short, the present invention provides a new type of complex which significantly increases the solubility of poorly soluble materials.
다른 양태로서, 본 발명은 상기 설명한 복합체를 포함하는 약학 또는 식품 조성물에 관한 것이다. In another aspect, the present invention relates to a pharmaceutical or food composition comprising the complex described above.
상기 복합체는 난용성 물질의 가용화제로 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초를 포함하는 것을 특징으로 한다. 상기 복합체는 난용성 물질의 가용성이 현저히 증가된 복합체로서, 이를 약학 또는 식품 조성물에 포함시켜 사용할 경우, 상기 약학 또는 식품 조성물은 경구 및 주사제형으로 제조하기 수월하고, 저장 안정성이 뛰어나며, 약물의 전달능력 및 체내 흡수율이 뛰어난 특징을 가지게 된다. The complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances. The complex is a complex in which the solubility of the poorly soluble substance is significantly increased. When used in a pharmaceutical or food composition, the complex is easy to prepare in oral and injectable form, has excellent storage stability, and delivers drugs. It is characterized by excellent ability and absorption in the body.
본 발명의 약학 조성물의 치료 질병은 상기 복합체에 포함되는 난용성 물질의 종류에 따라 달라질 수 있으며, 예를 들어, 파클리탁솔이 난용성 물질로 본 발명의 복합체에 포함된다면, 상기 조성물은 항암 용도 즉, 암의 예방 또는 치료용도로 사용될 수 있으며, 커큐민이 난용성 물질로 본 발명의 복합체에 포함된다면 커큐민의 의약 용도인 항종양 또는 항염증 용도로 사용할 수 있다. The therapeutic disease of the pharmaceutical composition of the present invention may vary depending on the type of poorly soluble substance included in the complex, for example, if paclitaxol is included in the complex of the present invention as a poorly soluble substance, the composition may be used for anticancer use. That is, it may be used for the prevention or treatment of cancer, and if curcumin is included in the complex of the present invention as a poorly soluble substance, it may be used for antitumor or anti-inflammatory use, which is a medicinal use of curcumin.
또한 본 발명의 조성물은 약학적으로 허용 가능한 담체를 추가로 포함할 수 있다. 약학적으로 허용 가능한 담체를 포함하는 상기 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테로 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.In addition, the composition of the present invention may further comprise a pharmaceutically acceptable carrier. The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
상기 약학 또는 식품 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제으로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있다.The pharmaceutical or food composition is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have either formulation.
상기 식품의 종류에는 특별한 제한은 없다. 상기 복합체를 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of the food to which the complex can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL당 일반적으로 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. Natural carbohydrates described above are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin, cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다. 그밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 과육의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 ~ 10 중량부의 범위에서 선택되는 것이 일반적이다. 이들 성분들은 독립적으로 또는 조합하여 사용할 수 있다. In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. The proportion of such pulp is not critical, but is generally selected in the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention. These components can be used independently or in combination.
또 다른 양태로서, 본 발명은 상기 설명한 복합체를 개체에 투여하여, 질환을 예방 또는 치료하는 방법에 관한 것이다.  In another aspect, the present invention relates to a method for preventing or treating a disease by administering the complex as described above to a subject.
상기 복합체는 난용성 물질의 가용성이 현저히 증가된 복합체로서, 상기 질환은 상기 난용성 물질의 종류에 따라 달라질 수 있다. The complex is a complex in which the solubility of the poorly soluble substance is significantly increased, and the disease may vary depending on the type of the poorly soluble substance.
본 발명에서 용어, "개체"란 질환에 감염될 수 있는 인간을 포함한 모든 동물을 의미하고 본 발명에서 설명한 복합체를 개체에 투여함으로써, 질환을 효과적으로 예방 및 치료할 수 있다. As used herein, the term "individual" means all animals including humans that may be infected with the disease, and by administering the complex described in the present invention to the individual, the disease can be effectively prevented and treated.
상기 복합체의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 본 발명의 복합체는 목적하는 바에 따라 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있으나, 이에 제한되지는 않는다. 또한 상기 복합체는 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.The route of administration of the complex can be administered via any general route as long as it can reach the target tissue. The complex of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration. The complex may also be administered by any device in which the active agent may migrate to the target cell.
또 다른 양태로서, 본 발명은 상기 설명한 복합체를 포함하는 화장료 조성물에 관한 것이다. In another aspect, the present invention relates to a cosmetic composition comprising the complex described above.
상기 복합체는 난용성 물질의 가용화제로 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초를 포함하는 것을 특징으로 한다. 상기 복합체는 난용성 물질의 가용성이 현저히 증가된 복합체로서, 이를 화장료 조성물에 포함시켜 사용할 경우, 화장품의 여러 형태로 제형화하기 수월하다. The complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances. The complex is a complex in which the solubility of the poorly soluble substance is significantly increased, and when it is used in a cosmetic composition, it is easy to be formulated into various forms of cosmetics.
본 발명의 화장료 조성물의 용도는 상기 복합체에 포함되는 난용성 물질의 종류에 따라 달라질 수 있다. 예를 들어, 상기 난용성 물질이 미백용도를 가진 것이라면, 상기 화장료 조성물은 미백용 화장료 조성물로 사용될 수 있다. The use of the cosmetic composition of the present invention may vary depending on the kind of poorly soluble substance included in the complex. For example, if the poorly soluble material has a whitening purpose, the cosmetic composition may be used as a cosmetic composition for whitening.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 수렴 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, astringent lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있다. 본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. 본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. 본 발명의 제형이 계면활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component. When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan. When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used. When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide ether. Sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또 다른 양태로서, 본 발명은 상기 설명한 복합체를 포함하는 사료 조성물에 관한 것이다. In another aspect, the present invention relates to a feed composition comprising the complex described above.
상기 복합체는 난용성 물질의 가용화제로 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초를 포함하는 것을 특징으로 한다. The complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
상기 사료 조성물은 사료 첨가제의 형태도 포함한다. The feed composition also includes the form of a feed additive.
본 발명의 사료 조성물의 용도는 상기 복합체에 포함되는 난용성 물질의 종류에 따라 달라질 수 있다. 예를 들어, 상기 난용성 물질이 커큐민일 경우, 커큐민의 인플루엔자 바이러스 치료 효과에 따라, 상기 사료 조성물은 인플루엔자 바이러스 감염 질환을 개선하고, 항 인플루엔자 효과를 갖는 사료 조성물로 사용될 수 있다. The use of the feed composition of the present invention may vary depending on the type of poorly soluble material included in the complex. For example, when the poorly soluble substance is curcumin, according to the influenza virus treatment effect of curcumin, the feed composition may be used as a feed composition to improve influenza virus infection disease and have an anti-influenza effect.
상기 사료는 영양가, 주성분, 유통, 수분 함량 배합상태 및 가공형태 등에 따라 여러 가지로 분류할 수 있으며, 상기 사료는 조사료, 농후사료, 보충사료, 단백질사료, 녹말사료, 지방질사료 또는 섬유질사료가 사용가능하나, 이에 한정하지 않는다. The feed may be classified into various types according to nutritional value, main ingredient, distribution, moisture content, blending state and processing type, and the feed may be used as a feed, a rich feed, a supplementary feed, a protein feed, a starch feed, a fat feed or a fiber feed. Possible, but not limited to.
또한, 상기 사료 조성물에는 추가적으로 가금류 및 가축 등에 허용되는 담체를 함유할 수 있다. 본 발명에 있어서는 상기 사료를 그대로 또는 공지의 담체, 안정제 등을 가할 수 있으며, 필요에 따라 비타민, 아미노산류, 미네랄 등의 각종 양분, 항산화제, 항생물질, 항균제 및 기타의 첨가제 등을 가할 수 있으며, 그 형상으로서는 분체, 과립, 펠릿, 현탁액 등의 적당한 상태일 수 있다. 본 발명의 사료 조성물을 공급하는 경우는 가금류 및 가축 등에 대하여 단독으로 또는 사료에 혼합하여 공급할 수 있다. In addition, the feed composition may additionally contain a carrier that is acceptable to poultry and livestock. In the present invention, the feed can be added as it is or a known carrier, stabilizer and the like, and various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives can be added as necessary. The shape may be in a suitable state such as powder, granules, pellets or suspension. In the case of supplying the feed composition of the present invention, poultry, livestock, and the like can be supplied alone or mixed with feed.
또 다른 양태로서, 본 발명은 상기 설명한 복합체를 포함하는 의약외품 조성물에 관한 것이다. In another aspect, the present invention relates to a quasi-drug composition comprising the complex described above.
상기 복합체는 난용성 물질의 가용화제로 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초를 포함하는 것을 특징으로 한다. The complex is characterized in that it comprises a steviol glycoside or stevia, or licorice containing the same as a solubilizer of poorly soluble substances.
본 발명의 의약외품 조성물의 용도는 상기 복합체에 포함되는 난용성 물질의 종류에 따라 달라질 수 있다. The use of the quasi-drug composition of the present invention may vary depending on the kind of poorly soluble substance included in the complex.
상기 의약외품의 종류는 이에 한정되는 것은 아니나, 예를 들어, 소독청결제, 소독제, 샤워폼, 가그린, 물티슈, 세제비누, 샴푸, 핸드워시, 가습기 충진제, 마스크, 연고제 또는 필터충진제일 수 있다.The type of quasi-drug is not limited thereto, but may be, for example, a disinfectant cleaner, a disinfectant, a shower foam, a gagreen, a wet tissue, a detergent soap, a shampoo, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.
또 다른 양태로서, 본 발명은 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초, 및 난용성 물질을 혼합하는 제1단계; 및 상기 제1단계에서 얻어진 혼합물에 마이크로웨이브(microwave)를 처리하는 제2단계를 포함하는, 가용성이 증가된 난용성 물질 함유 복합체의 제조방법에 관한 것이다. In another aspect, the present invention is a steviol glycoside or stevia, or licorice comprising the same, and the first step of mixing a poorly soluble material; And a second step of subjecting the mixture obtained in the first step to microwaves (microwaves).
상기 제조방법에 있어서, 스테비올 배당체, 스테비아, 감초 및 난용성 물질은 상기 설명한 내용과 동일하다. In the above production method, steviol glycosides, stevia, licorice and poorly soluble substances are the same as described above.
상기 스테비올 배당체는 스테비아 식물에서 높은 함량으로 발견되는 스테비오사이드(stevioside), 레바우디오사이드(rebaudioside) A, 레바우디오사이드 C, 둘코사이드(dulcoside) A 뿐만 아니라, 레바우디오사이드 B, D, E, 루부소사이드, 스테비올 비오사이드, 스테비올 모노사이드, SWETA, SWETA ML01, SWETA75 등이 포함될 수 있으며, 이에 제한되지는 않는다. The steviol glycosides are stevioside, rebaudioside A, rebaudioside C, dulcoside A, which are found in high content in stevia plants, as well as rebaudioside B, D , E, rubisoside, steviol bioside, steviol monoside, SWETA, SWETA ML01, SWETA75 and the like can be included, but is not limited thereto.
또한 난용성 물질은 상기 설명한 바와 같이, 용해도가 낮은 물질이면 종류에 제한없이 사용할 수 있다. As described above, the poorly soluble substance can be used without limitation as long as it is a substance having low solubility.
상기 제1단계에서, 본 발명은 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초, 및 난용성 물질을 용매에 혼합하거나, 또는 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초가 포함된 용액에 난용성 물질을 첨가하여 혼합할 수 있다. In the first step, the present invention is steviol glycosides or stevia, or licorice containing the same, and the poorly soluble substances are mixed in a solvent, or steviol glycosides or stevia, or licorice containing the same, poorly soluble in the solution The material can be added and mixed.
또한 상기 제1단계에서 스테비올 배당체 또는 스테비아는 0.1 내지 25%(w/v)의 농도(고형분 기준)로 포함되는 것이 바람직하며, 상기 감초는 0.1 내지 30%(w/v)의 농도(고형분 기준)로 포함되는 것이 바람직하다. 또한, 상기 제1단계는 60℃ 내지 80℃에서 수행되는 것이 바람직하며, 보다 바람직하게는 65℃ 내지 75℃, 보다 더 바람직하게는 70℃에서 수행하는 것이다. In addition, the steviol glycoside or stevia in the first step is preferably included in a concentration (solid basis) of 0.1 to 25% (w / v), the licorice is a concentration (solid content of 0.1 to 30% (w / v) It is preferable to include as a reference). In addition, the first step is preferably carried out at 60 ℃ to 80 ℃, more preferably at 65 ℃ to 75 ℃, even more preferably at 70 ℃.
상기 마이크로웨이브를 처리하는 제2단계에서, 마이크로웨이브를 처리하는 방법은 이에 제한되지는 않으나, 작동중인 전자레인지(microwave oven; 일반 가정용 또는 합성 전용 모두 포함)에 반응시킬 수 있다. 또한, 상기 마이크로웨이브는 일반 가정용 전자레인지에서 600 W 내지 800 W로 1분 내지 20분간 처리하는 것이 바람직하며, 보다 바람직하게는, 650 W 내지 750 W로 10분 내지 20분간 처리하는 것이며, 보다 더 바람직하게는, 700W로 15분간 처리하는 것이다. 또한, 상기 마이크로웨이브는 합성 전용 전자레인지에서 50 W 내지 300 W로 1분 내지 100분간 처리될 수 있으며, 바람직하게는 140 W 내지 240 W로 1분 내지 20분간 처리하는 것이다. 보다 바람직하게는, 160W 내지 220 W로 6분 내지 12분간 처리하는 것이며, 보다 더 바람직하게는, 180 W 내지 200 W로 7분 내지 10분간 처리하는 것이다. 마이크로웨이브 처리 횟수는 제한이 없으나, 2회 이상 수행하는 것이 바람직하다. 또한, 각 반응 사이에 복합체를 식히는 단계를 추가하여 얻어질 수 있으며, 상기 제형은 전자레인지에 반응시키기 전에 초음파 처리하는 단계를 추가로 하여 얻어질 수 있다. In the second step of processing the microwave, the method of processing the microwave is not limited to this, but may be reacted to a microwave oven in operation (including general household or synthetic only). In addition, the microwave is preferably treated for 1 minute to 20 minutes at 600 W to 800 W in a general household microwave oven, and more preferably, 10 to 20 minutes at 650 W to 750 W, even more. Preferably, the treatment is performed at 700 W for 15 minutes. In addition, the microwave can be treated for 1 minute to 100 minutes at 50 W to 300 W in a microwave for synthesis only, preferably 1 to 20 minutes to 140 W to 240 W. More preferably, the treatment is carried out at 160W to 220W for 6 minutes to 12 minutes, and even more preferably at 180W to 200W for 7 minutes to 10 minutes. The number of microwave treatments is not limited, but is preferably performed two or more times. In addition, it can be obtained by adding a step of cooling the complex between each reaction, the formulation can be obtained by the further step of sonicating before reacting in the microwave.
본 발명의 실시예에서는 스테비올 배당체 또는 이를 포함하는 스테비아 추출물, 또는 감초 추출물, 및 난용성 물질을 혼합하는 제 1단계를 수행한 후, 난용성 물질의 가용화도를 측정한 결과, 난용성 물질을 물에 용해시킨 것에 비해 난용성 물질의 가용화가 현저히 증가되었다. 또한, 이에 마이크로웨이브를 처리하는 제2단계를 수행한 후, 난용성 물질의 가용화도를 측정한 결과, 물에 용해시킨 경우, 제 1단계를 수행한 후 초음파 처리, 또는 습윤 멸균기를 처리한 경우에 비해 난용성 물질의 가용화도가 현저히 증가된 것을 확인할 수 있었다. In an embodiment of the present invention, after performing the first step of mixing the steviol glycosides or stevia extract or licorice extract containing the same, and the poorly soluble substance, the solubility of the poorly soluble substance was measured, The solubilization of poorly soluble substances was significantly increased compared to those dissolved in water. In addition, after performing the second step of treating the microwave, the solubility of the poorly soluble substance was measured, and when dissolved in water, after the first step after sonication or wet sterilizer treatment It can be seen that the solubility of the poorly soluble substance was significantly increased.
또 다른 양태로서, 본 발명은 감초를 유효성분으로 함유하는 가용화제에 관한 것이다. As another aspect, the present invention relates to a solubilizer containing licorice as an active ingredient.
본 발명의 실시예에서는 감초 추출물이 포함된 용액에 난용성 물질을 용해시킨 경우, 물에 난용성 물질을 녹인 경우에 비해 현저하게 난용성 물질의 가용화도가 증가되는 것을 확인하였다. 따라서, 본 발명의 감초 추출물의 형태를 포함하는 감초는 난용성 물질의 가용화를 촉진시켜 주는, 가용화제로서 사용할 수 있다. In the embodiment of the present invention, when the poorly soluble substance was dissolved in the solution containing licorice extract, it was confirmed that the solubility of the poorly soluble substance is significantly increased compared to the case of dissolving the poorly soluble substance in water. Therefore, licorice comprising the form of the licorice extract of the present invention can be used as a solubilizer, which promotes solubilization of poorly soluble substances.
상기 가용화제에서 감초 추출물은 이에 제한되지 않으나, 0.1 내지 25%(w/v)의 농도로 포함되는 것이 바람직하다. Licorice extract in the solubilizer is not limited thereto, but is preferably included in a concentration of 0.1 to 25% (w / v).
또 다른 양태로서, 본 발명은 감초와 난용성 물질을 혼합하는 단계를 포함하는, 난용성 물질을 가용화시키는 방법에 관한 것이다. In another aspect, the present invention relates to a method of solubilizing poorly soluble materials, comprising mixing licorice with poorly soluble materials.
상기 감초는 감초 추출물일 수 있다. The licorice may be licorice extract.
상기 감초와 난용성 물질을 혼합하는 단계는, 감초가 포함된 용액에 난용성 물질을 첨가하여 감초 추출물과 난용성 물질을 혼합하는 단계로서 수행될 수 있다. 또는 용매에서 감초 추출물과 난용성 물질을 혼합시킴으로서 수행될 수 있다. The mixing of the licorice and the poorly soluble substance may be performed as a step of mixing the licorice extract and the poorly soluble substance by adding a poorly soluble substance to the solution containing licorice. Or by mixing licorice extract and poorly soluble material in a solvent.
상기와 같이 감초와 난용성 물질을 혼합하게 되면, 감초가 난용성 물질의 가용화도를 증가시켜, 난용성 물질을 가용화시킬 수 있다. When the licorice and the poorly soluble material are mixed as described above, the licorice may increase the solubility of the poorly soluble material and solubilize the poorly soluble material.
상기 방법은, 감초와 난용성 물질을 혼합한 후, 마이크로웨이브를 처리하는 단계를 추가로 포함할 수 있다. The method may further comprise treating the microwaves after mixing licorice and the poorly soluble material.
또 다른 양태로서, 본 발명은 가용화제의 제조에 있어서 감초의 용도를 제공한다. In another aspect, the present invention provides the use of licorice in the preparation of solubilizers.
상기 감초는 감초 추출물이 바람직하다. The licorice is preferably licorice extract.
본 발명의 일 실시예에서는 감초 추출물이 포함된 용액에 난용성 물질을 녹인 경우, 감초 추출물이 포함되지 않은 용액에 난용성 물질을 녹인 경우보다 난용성 물질의 용해도가 현저히 증가되는 것을 확인할 수 있었다. 따라서, 감초는 난용성 물질의 가용화제를 제조하는데 사용될 수 있는 용도를 가진다. In an embodiment of the present invention, when the poorly soluble substance was dissolved in the solution containing licorice extract, it was confirmed that the solubility of the poorly soluble substance was significantly increased than when the poorly soluble substance was dissolved in the solution not containing licorice extract. Thus, licorice has a use that can be used to prepare solubilizers of poorly soluble materials.
이하, 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
실시예 1: 울금 추출물 및 커큐민의 제조Example 1 Preparation of Turmeric Extract and Curcumin
1-1. 울금 추출물의 제조1-1. Preparation of Turmeric Extract
본 실시예에서 사용한 울금은 일반적으로 한약재상이나 시장에서 구입할 수 있는 것으로 가을울금(Curcuma longa Linne)의 덩이뿌리(Radix) 부위를 그대로 쪄서 말린 것을 구입한 후 본 발명의 추출물을 효율적으로 얻기 위하여 파우더 형태로 분쇄하여 사용하였다. 울금 1.6 kg에 100% 에탄올(EtOH) 7.5 ℓ를 가하여 실온에서 5일 방치하고 여과지로 여과하고 농축하여 울금 에탄올 추출물(170 g)을 얻었다.The turmeric used in the present embodiment is generally available in Chinese medicine or on the market, and is dried in the form of dried Root of Curcuma longa Linne and then dried to obtain powder of the present invention to efficiently obtain the extract of the present invention. It was used by grinding. 7.5 L of 100% ethanol (EtOH) was added to 1.6 kg of turmeric, and the mixture was left to stand at room temperature for 5 days, filtered through a filter paper, and concentrated to obtain turmeric ethanol extract (170 g).
1-2. 울금 추출물로부터 울금 분획물 및 커큐미노이드계 화합물의 분리 및 정제1-2. Isolation and Purification of Turmeric Fractions and Curcuminoid Compounds from Turmeric Extracts
상기 실시예 1-1에서 수득한 울금의 에탄올추출물 170 g에 물 1ℓ를 넣어 현탁시켰다. 이를 분별 깔대기에 넣고, n-헥산 및 에틸아세테이트를 순서대로 이용하여 분별 추출하여 n-헥산 가용추출물 (23 g), 에틸아세테이트 가용추출물 (85 g) 및 물 가용추출물 (34 g)을 수득하였다. 170 g of ethanol extract of turmeric obtained in Example 1-1 was added and suspended in 1 L of water. This was placed in a separatory funnel, and fractional extraction using n-hexane and ethyl acetate in order to obtain n-hexane soluble extract (23 g), ethyl acetate soluble extract (85 g) and water soluble extract (34 g).
상기에서 수득한 에틸아세테이트 가용추출물 85 g을 클로로포름, 메탄올 및 이들의 혼합용매 (80:1 ~ 1:1)를 이동상으로 하여 실리카겔 컬럼 크로마토그래피[실리카겔 500 g, 70~230 메쉬(mesh)]를 수행하여 15개의 분획물(Fr.-1~15)로 분리하였다. 이중 여섯 번째 분획물(Fr.-6, 16 g)은 n-헥산 : 에틸아세테이트(20:1 ~ 1:1 (v/v))의 혼합용매를 이동상으로 하여 다시 실리카겔 컬럼 크로마토그래피 (30 g, 230 ~ 400 메쉬)를 수행하여 5개의 분획물(Fr.-6-1~5)을 얻었다. 85 g of the ethyl acetate soluble extract obtained above was subjected to silica gel column chromatography [silica gel 500 g, 70 to 230 mesh] using chloroform, methanol, and a mixed solvent thereof (80: 1 to 1: 1) as a mobile phase. 15 fractions (Fr.-1-15) were separated. The sixth fraction (Fr.-6, 16 g) was purified by silica gel column chromatography (30 g, 30%, n-hexane: ethyl acetate (20: 1 to 1: 1 (v / v)) as a mobile solvent. 230 to 400 mesh) was carried out to obtain five fractions (Fr.-6-1-5).
그 중 Fr.-6-2~3 분획물(11 g)에 대해 클로로포름, 메탄올 및 이들의 혼합용매 (80:1 ~ 4:1)를 이동상으로 실리카겔 컬럼 크로마토그래피를 수행하여 획득한 분획물을 대상으로 제조용 TLC(preparative TLC)법으로 전개[(n-헥산:에틸아세테이트=4:1 (v/v)]하여 커큐민(curcumin) (8 g)을 수득하였다. 또한, 여덟 번째 분획물 (Fr.-8, 14 g)은 n-헥산 : 에틸아세테이트(20:1 ~ 1:1 (v/v)) 및 클로로포름 : 메탄올 (80:1 ~ 20:1 (v/v))의 혼합용매를 이동상으로 하여 실리카겔 컬럼 크로마토그래피 (30 g, 230 ~ 400 메쉬)를 반복적으로 수행하여 데메톡시커큐민(Demethoxycurcumin) (0.4 g)과 비스데메톡시커큐민(Bisdemethoxycurcumin) (0.2 g)을 수득하였다.Among the fractions obtained by performing silica gel column chromatography on Fr.-6-2-3 fractions (11 g) with chloroform, methanol and their mixed solvents (80: 1 to 4: 1) as mobile phases. Development was carried out by preparative TLC ([n-hexane: ethylacetate = 4: 1 (v / v)) to give curcumin (8 g), and the eighth fraction (Fr.-8) , 14 g) was prepared using a mixed solvent of n-hexane: ethyl acetate (20: 1 to 1: 1 (v / v)) and chloroform: methanol (80: 1 to 20: 1 (v / v)) as a mobile phase. Silica gel column chromatography (30 g, 230-400 mesh) was repeatedly performed to obtain Demethoxycurcumin (0.4 g) and Bisdemethoxycurcumin (0.2 g).
실시예 2: 레스베라트롤 및 글루코실 레스베라트롤의 제조Example 2: Preparation of Resveratrol and Glucosyl Resveratrol
호장근은 물로 깨끗이 세척하여 그늘에서 건조한 후, 와링 브랜드로 분말화 시켰다. 분말화된 호장근 3.6 ㎏을 에탄올 20 ℓ에 넣고 실온에서 7일간 냉침 추출한 후, 여지(와트만사, 미국)로 감압 여과하였다. 그런 다음, 여과 추출물은 진공회전농축기로 실온에서 에탄올 용매를 제거한 후 추출된 잔사로서 호장근 조추출물 146 g을 수득하였다.Ho Jang Keun was washed with water, dried in the shade, and then powdered with Waring brand. 3.6 kg of powdered ephedra root was added to 20 L of ethanol, and extracted by cold extraction at room temperature for 7 days, followed by filtration under reduced pressure (Watman, USA). Then, the filtrate extract was removed from the ethanol solvent at room temperature with a vacuum rotary concentrator to obtain 146 g of Keunjangeun crude extract as a residue.
상기 조추출물은 물 1 ℓ에 현탁 시킨 후 동량의 에틸아세테이트를 가하여 혼합하여 분획하였으며, 이 과정을 4회 반복하여 에틸아세테이트 분획물 4 ℓ를 수득하였다. 이 에틸아세테이트 가용성 분획물을 감압 농축하여 에틸아세테이트 가용 추출물 80 g을 수득하였다.The crude extract was suspended in 1 L of water, mixed with the same amount of ethyl acetate, and fractionated. The procedure was repeated four times to obtain 4 L of ethyl acetate fraction. The ethyl acetate soluble fraction was concentrated under reduced pressure to obtain 80 g of an ethyl acetate soluble extract.
상기에서 얻은 에틸아세테이트 가용 추출물 중 40 g을, 클로로포름:메탄올 = (100:0 ~ 1:1)로 구성된 단계농도 구배(step gradient) 용매 시스템을 이용하여 실리카겔 컬럼 크로마토그래피를 행하여 레스베라트롤(resveratrol)이 함유된 클로로포름:메탄올 = 20:1 분획물 830 mg 을 수득하였다.40 g of the ethyl acetate soluble extract obtained above was subjected to silica gel column chromatography using a step gradient solvent system consisting of chloroform: methanol = (100: 0 to 1: 1) to obtain resveratrol. 830 mg of chloroform: methanol = 20: 1 fractions were obtained.
상기에서 얻어진 호장근 에탄올 추출물 및 에틸아세테이트 분획물, 그리고 에틸아세테이트 분획 컬럼 크로마토그래피 중 클로로포름:메탄올 = 20:1 분획물에 대하여 레스베라트롤 함유 정도를 확인하기 위하여 LC-MS를 이용하여 분석을 수행하였다.The chloroform: methanol = 20: 1 fraction in the E. coli ethanol extract, ethyl acetate fraction, and ethyl acetate fraction column chromatography obtained above was analyzed using LC-MS to confirm the resveratrol content.
기타, 글리시리진산(glycyrrhizinic acid), 글루코실 레스베라트롤(glucosyl resveratrol), 레바우디오사이드(rebaudioside)는 시그마사에서 구입하였고, 파클리탁솔(paclitaxol)은 삼양제넥스(주)에서 제공되었고, 스테비오사이드 및 감초추출물은 대평(주)에서 구입하여 실험에 사용되었다. 또한, 스테비올 배당체인 효소처리스테비아 (SWETA), 스테비올 배당체를 75% 함유한 SWETA75, 스테비올 배당체를 50% 함유한 ML01은 케미넥스(주)에서 구입하였다. Others, glycyrrhizinic acid, glucosyl resveratrol and rebaudioside were purchased from Sigma, and paclitaxol was provided by Samyang Genex, Inc., stevioside and Licorice extract was purchased from Daepyeong Co., Ltd. was used in the experiment. In addition, the enzyme treatment stevia (SWETA) which is a steviol glycoside, SWETA75 containing 75% of steviol glycosides, and ML01 containing 50% of steviol glycosides were purchased from Cheminex.
실시예 3: 스테비올 배당체를 활용한 커큐민의 가용화Example 3: Solubilization of Curcumin Using Steviol Glycosides
실시예 1의 방법으로 제조된 커큐민 10 mg/ml을 각각의 10% (w/v)스테비올 배당체 용액(SWETA, 효소처리 스테비오사이드, 레바우디오사이드, SWETA ML01, SWETA75, 스테비오사이드)에 대하여 녹이고, 초음파를 이용하여 10분간 처리하였다. 각 용매로부터 가용화된 커큐민의 양을 HPLC를 이용하여 정량하였으며, 그 결과는 하기 표 1(스테비올 배당체 성분에 따른 커큐민의 가용화 정도)과 같았다. 하기 표 1은 커큐민의 가용화 정도를 mg/L의 양으로 표시한 것이다. 10 mg / ml of curcumin prepared by the method of Example 1 was prepared for each 10% (w / v) steviol glycoside solution (SWETA, enzymatically treated stevioside, rebaudioside, SWETA ML01, SWETA75, stevioside). It melt | dissolved and it processed for 10 minutes using the ultrasonic wave. The amount of curcumin solubilized from each solvent was quantified using HPLC, and the results were as shown in Table 1 (degree of solubilization of curcumin according to the steviol glycoside component). Table 1 below shows the degree of solubilization of curcumin in the amount of mg / L.
표 1
SWETA 효소처리 스테비오사이드 레바우디오사이드 SWETAML01 SWETA75 스테비오사이드
녹은양(mg/L) 11 270 350 430 600 750 850
Table 1
water SWETA Enzyme Treatment Stevioside Rebaudioside SWETAML01 SWETA75 Stevioside
Molten amount (mg / L) 11 270 350 430 600 750 850
표 1의 결과와 같이 스테비오사이드가 포함된 용액에서 커큐민의 가용화정도가 가장 탁월하였다. 따라서 스테비올 배당체 중에서 커큐민의 가용화제로서 가장 우수한 스테비오사이드를 사용하여 다양한 조건에서 실험을 실시하였다. As shown in Table 1, the solubilization of curcumin was the best in the solution containing stevioside. Therefore, experiments were conducted under various conditions using stevioside, which is the best solubilizer of curcumin among steviol glycosides.
먼저, 커큐민을 스테비오사이드가 포함된 용액에 녹일때 온도를 30℃, 50℃, 70℃로 설정하여, 어느 온도에서 커큐민의 가용화가 가장 높아지는지를 확인하였다. 그 결과, 30℃에서는 커큐민이 110 mg/L 용해되었고, 50℃에서는 170 mg/L 용해되었으며, 70℃에서는 390 mg/L 용해되었다. 즉, 70℃에서 가장 커큐민의 용해도가 증가됨을 확인할 수 있었다(도 1).First, when curcumin was dissolved in a solution containing stevioside, the temperature was set to 30 ° C., 50 ° C., and 70 ° C., and it was confirmed at which temperature the solubilization of curcumin was the highest. As a result, curcumin was dissolved at 110 mg / L at 30 ° C, 170 mg / L at 50 ° C, and 390 mg / L at 70 ° C. That is, it was confirmed that the solubility of curcumin was most increased at 70 ℃ (Fig. 1).
또한, 커큐민 10 mg/ml을 스테비오사이드 용액에 녹이고 초음파 처리한 후, 초음파 처리, 습윤 멸균기(autoclave; 121℃, 15 psi, 15분간), 또는 가정용 마이크로웨이브(microwave; 700W의 전자레인지에서 15분간 반응시킴)를 각각 15분간 처리하였다. 상기 3가지 조건에서 커큐민의 가용화 정도를 확인하였으며, 그 결과는 하기 표 2와 같았다. In addition, 10 mg / ml of curcumin is dissolved in stevioside solution and sonicated, followed by sonication, autoclave (121 ° C., 15 psi, 15 minutes), or microwave for 15 minutes in a microwave oven at 700 W. Reaction) were treated for 15 minutes each. The degree of solubilization of curcumin was confirmed under the three conditions, and the results are shown in Table 2 below.
표 2
스테비오사이드 농도, % (w/v) 커큐민 가용화 (mg/L)
초음파처리 습윤 멸균기 마이크로웨이브
0.5 48 57 120
2 90 100 300
5 300 500 1,500
10 850 1,300 3,500
TABLE 2
Stevioside concentration,% (w / v) Curcumin Solubilization (mg / L)
Ultrasonic treatment Wet Sterilizer Microwave
0.5 48 57 120
2 90 100 300
5 300 500 1,500
10 850 1,300 3,500
상기 표 2의 결과와 같이, 10% (w/v)의 스테비오사이드와 함께 처리하였을 때, 커큐민의 가용화는 초음파를 처리한 경우보다 15분간의 습윤 멸균기를 처리한 경우에 더 높았으며, 커큐민의 녹은 양이 습윤 멸균기를 처리한 경우에서 450 mg/mL 향상되었다. 또한, 마이크로웨이브를 처리한 경우에는 초음파 처리 또는 습윤 멸균기를 처리한 경우보다 커큐민의 가용화도를 현저하게 증가시켰으며, 초음파 처리한 경우보다 약 2,650 mg/L의 커큐민이 더 용해되어 가용화도가 약 4.1배 향상되었음을 확인할 수 있었다(도 2). As shown in Table 2, when treated with 10% (w / v) stevioside, the solubilization of curcumin was higher when treated with a 15-minute wet sterilizer than when treated with ultrasound, Molten amount improved 450 mg / mL when treated with a wet sterilizer. In addition, the microwave treatment significantly increased the solubilization of curcumin than the sonication or wet sterilizer, and about 2,650 mg / L of curcumin was more dissolved than sonication, so that the degree of solubility was weak. It was confirmed that it was improved 4.1 times (FIG. 2).
상기 결과로부터 커큐민을 스테비오사이드 용액에 녹이면 커큐민의 가용화도를 증가시킬 수 있으며, 더 나아가 마이크로웨이브 처리단계를 추가로 수행해주면, 커큐민의 가용화도가 약 4배 이상 증가시킬 수 있음을 알 수 있었다. 또한, 커큐민과 스테비오사이드의 혼합물을 습윤 멸균기의 고온(121℃)에서 처리한 경우보다 마이크로웨이브를 처리한 경우에 가용화도가 약 3배 정도 증가되었는 바, 이로부터 마이크로웨이브 처리에 의해 단순히 온도가 증가되어 가용화도가 증가된 것이 아님을 알 수 있었다. From the above results, it was found that dissolution of curcumin in the stevioside solution can increase the solubility of curcumin, and furthermore, if the microwave treatment step is further performed, the solubility of curcumin can be increased by about four times or more. In addition, the solubility was increased by about three times when the mixture of curcumin and stevioside was treated at a high temperature (121 ° C.) of the wet sterilizer. From this, the temperature was simply increased by microwave treatment. It was found that the solubility was not increased due to the increase.
또한, 합성 전용 마이크로웨이브(CEM사 Discover legacy systems 모델)를 이용하여 가용화된 커큐민을 최적화하였다. 기본적인 실험을 통해 마이크로웨이브 파워는 (50-200 W), 스테비오사이드 농도 (50-200 mg/L), 커큐민농도 (20-200 mg/L), 반응시간은 1-10분 등의 4가지 인자에서 표면반응 해석방법에 의해 최적화 하였다(표 3).In addition, solubilized curcumin was optimized using a synthetic-only microwave (CEM's Discover legacy systems model). Basic experiments show four factors: microwave power (50-200 W), stevioside concentration (50-200 mg / L), curcumin concentration (20-200 mg / L), and reaction time 1-10 minutes. Optimized by surface reaction analysis method at (Table 3).
표 3
Figure PCTKR2012006069-appb-T000001
TABLE 3
Figure PCTKR2012006069-appb-T000001
각각 두 개의 조건에서의 상관관계를 분석해본 결과는 도 3과 같았다. 결과적으로 최적화 프로그램에서 얻어진 최적화된 식은 하기와 같았다. y=4.94+4.21x 1+3.42x 2+1.33x 3+1.29x 4+1.88x 1 x 2+2.08x 1 x 3+0.40x 1 x 4+1.31x 2 x 3+0.91x 2 x 4 +0.75x 3 x 40.16x 1 2+0.35x 2 2+0.37x 3 21.55x 4 2 였으며, 마이크로웨이브 파워는 189W, 195 mg/L의 스테비오사이드, 183 mg/L의 커큐민을 함유한 용액을 8.9분 처리하면 17,000 mg/L가 가용화됨을 예상할 수 있었다. 또한, 동일한 조건에서 3회 반복실험을 실시한 결과, 16,950 mg/L의 커큐민이 가용화됨을 알 수 있었다.The results of analyzing the correlations under the two conditions were as shown in FIG. 3. As a result, the optimized equation obtained in the optimizer was as follows. y = 4.94 + 4.21x                 One+3.42x                 2+1.33x                 3+1.29x                 4+1.88x                 One                 x                 2+2.08x                 One                 x                 3+0.40x                 One                 x                 4+1.31x                 2                 x                 3+0.91x                 2                 x                 4+0.75x                 3                 x                 40.16x                 One                 2+0.35x                 2                 2+0.37x                 3                 21.55x                 4                 2The microwave power was expected to solubilize 17,000 mg / L after 8.9 min of a solution containing 189 W, 195 mg / L stevioside, and 183 mg / L curcumin. In addition, three repeated experiments under the same conditions showed that 16,950 mg / L of curcumin was solubilized.
실시예 4: 감초추출물을 이용한 커큐민의 가용화Example 4: Solubilization of Curcumin Using Licorice Extract
실시예 1의 방법으로 제조된 커큐민 10 mg/ml을 각각의 1-5% (w/v) 감초 추출물 용액에 대하여 녹이고, 초음파를 이용하여 10분간 처리하였다.각 용매로부터 가용화된 커큐민의 양을 HPLC를 이용하여 정량하였으며, 그 결과는 하기 표 4과 같다. 10 mg / ml of curcumin prepared by the method of Example 1 was dissolved for each 1-5% (w / v) licorice extract solution and treated with ultrasonic waves for 10 minutes. The amount of curcumin solubilized from each solvent was measured. Quantitation using HPLC, the results are shown in Table 4 below.
표 4
감초 추출물의 농도 (%, w/v)
1% (w/v) 감초추출물 2% (w/v) 감초 추출물 3% (w/v) 감초추출물 4% (w/v) 감초추출물 5% (w/v) 감초추출물
녹은양(mg/L) 280 320 430 510 620
Table 4
Concentration of Licorice Extract (%, w / v)
1% (w / v) Licorice Extract 2% (w / v) Licorice Extract 3% (w / v) Licorice Extract 4% (w / v) Licorice Extract 5% (w / v) Licorice Extract
Molten amount (mg / L) 280 320 430 510 620
표 4에 나타나 있듯이, 낮은 농도 보다 높은 감초 추출물의 농도 조건에서 커큐민의 가용화가 탁월하였다. 또한, 커큐민 10 mg/ml을 0.5, 2, 5, 10% (w/v)의 감초 추출물 용액에 녹이고 초음파 처리한 후, 초음파 처리, 습윤 멸균기(121℃, 15 psi, 15분간), 마이크로웨이브에 각각 15분간 처리하였다. 감초 추출물의 농도와 상기 3가지 후처리에 따른 커큐민의 가용화 정도는 하기 표 5에 나타내었다. As shown in Table 4, the solubilization of curcumin was excellent at the concentration of licorice extract higher than the low concentration. In addition, 10 mg / ml curcumin was dissolved in 0.5, 2, 5, 10% (w / v) licorice extract solution and sonicated, followed by sonication, wet sterilizer (121 ° C., 15 psi, 15 minutes), microwave 15 minutes each. The concentration of licorice extract and the degree of solubilization of curcumin according to the three post-treatments are shown in Table 5 below.
표 5
감초 추출물의 농도, % (w/v) 커큐민 가용화 (mg/L)
초음파처리 습윤 멸균기 마이크로웨이브
0.5 48 57 100
2 100 100 1,700
5 300 400 3,800
10 1200 1,500 5,100
Table 5
Concentration of licorice extract,% (w / v) Curcumin Solubilization (mg / L)
Ultrasonic treatment Wet Sterilizer Microwave
0.5 48 57 100
2 100 100 1,700
5 300 400 3,800
10 1200 1,500 5,100
표 5의 결과와 같이, 커큐민의 가용화는 초음파를 처리한 경우보다 15분간의 습윤 멸균기를 처리한 경우에 더 높았으며, 커큐민의 녹은 양은 약 300 mg/mL 향상되었다. 또한, 마이크로웨이브를 처리한 경우에는 초음파 처리 또는 습윤 멸균기를 처리한 경우보다 커큐민의 가용화도를 현저하게 증가시켰으며, 초음파 처리한 경우보다 약 3,900 mg/L의 커큐민이 더 용해되어 가용화도가 약 4.16배 향상되었음을 확인할 수 있었다(도 4). 또한, 마이크로웨이브를 사용한다면 물에서 거의 가용화하지 않던 커큐민(11 mg/L)이 0.5% (w/v)의 감초 추출물 용액에서 100 mg/L 정도 녹으며, 10% (w/v)의 감초 추출물 용액에서 5,100 mg/L 까지 녹게 되었다. 상기의 결과는 지금까지 알려진 커큐민의 최고의 가용화 정도이며, 물에서의 가용화 정도와 비교하면 약 463배 향상된 결과였다. As shown in Table 5, the solubilization of curcumin was higher with 15 minutes of wet sterilizer than with sonication, and the amount of curcumin improved about 300 mg / mL. In addition, the microwave treatment significantly increased the solubilization of curcumin than the sonication or wet sterilizer, and about 3,900 mg / L of curcumin was dissolved more so than sonication. It was confirmed that 4.16 times improved (FIG. 4). In addition, if microwave was used, curcumin (11 mg / L), which was hardly solubilized in water, dissolved about 100 mg / L in 0.5% (w / v) licorice extract solution and 10% (w / v) licorice. It was dissolved up to 5,100 mg / L in the extract solution. The above result is the highest degree of solubilization of curcumin so far known, which is about 463 times improved compared to the degree of solubilization in water.
실시예 5: 스테비올 배당체를 이용한 레스베라트롤 및 글루코실 레스베라트롤의 가용화Example 5: Solubilization of Resveratrol and Glucosyl Resveratrol Using Steviol Glycosides
시그마사로부터 구입한 글루코실 레스베라트롤과 실시예 2의 방법으로 제조된 레스베라트롤 20 mg/ml을 각각의 0-20% (w/v) 스테비오사이드 또는 감초 추출물 용액에 대하여 녹이고, 70℃에서 초음파를 이용하여 15분간 처리하였다. 또한 이에 마이크로웨이브를 이용하여 15분씩 2번 처리하여 각각의 용매로부터 가용화된 레스베라트롤, 글루코실 레스베라트롤의 양을 HPLC를 이용하여 정량하였다. 상기 결과를 마이크로웨이브를 처리하지 않고, 초음파 처리만 한 경우와 비교하였으며, 그 결과는 하기 표 6와 같았다.Glucosyl resveratrol purchased from Sigma and 20 mg / ml of resveratrol prepared by the method of Example 2 were dissolved for each 0-20% (w / v) stevioside or licorice extract solution, and ultrasonically used at 70 ° C. Treated for 15 minutes. In addition, the microwaves were treated twice each for 15 minutes to quantify the amounts of resveratrol and glucosyl resveratrol solubilized from each solvent using HPLC. The results were compared with the case of only ultrasonic treatment without microwave treatment, and the results are shown in Table 6 below.
표 6
스테비오사이드 농도, % (w/v) 가용화된 레스베라트롤 (mg/L) 가용화된 글루코실 레스베라트롤 (mg/L)
초음파처리 마이크로웨이브 초음파처리 마이크로웨이브
0 10 10 50 530
2.5 900 2,200 1,100 5,800
5 1,600 4,900 3,100 8,300
10 3,300 6,300 4,200 12,200
20 6,200 9,400 8,500 14,300
Table 6
Stevioside concentration,% (w / v) Solubilized Resveratrol (mg / L) Solubilized Glucosyl Resveratrol (mg / L)
Ultrasonic treatment Microwave Ultrasonic treatment Microwave
0 10 10 50 530
2.5 900 2,200 1,100 5,800
5 1,600 4,900 3,100 8,300
10 3,300 6,300 4,200 12,200
20 6,200 9,400 8,500 14,300
상기 표 6에서와 같이, 스테비오사이드를 20% (w/v) 첨가한 시료에서 최종적으로 가용화된 레스베라트롤의 양은 6,200 mg/L 였으며, 이는 스테비오사이드가 포함되지 않은 용액에서 가용화된 레스베라트롤 10 mg/L에 비해 가용화도가 현저히 증가됨을 확인할 수 있었다. 또한, 스테비오사이드가 포함된 용액에 레스베라트롤을 녹인 후, 마이크로웨이브를 처리한 경우에는 가용화된 레스베라트롤의 양이 9,400 mg/L 까지 향상됨을 확인하였다. As shown in Table 6, the amount of resveratrol finally solubilized in the sample to which 20% (w / v) of stevioside was added was 6,200 mg / L, which was 10 mg / L solubilized resveratrol in a solution containing no stevioside It was confirmed that the solubility was significantly increased compared to. In addition, after dissolving resveratrol in a solution containing stevioside, it was confirmed that the amount of solubilized resveratrol was improved to 9,400 mg / L when the microwave treatment.
또한, 스테비오사이드를 20% (w/v) 첨가한 시료에서 최종적으로 가용화된 글루코실 레스베라트롤의 양은 8,500 mg/L 였으며, 이는 스테비오사이드가 포함되지 않은 용액에서 가용화된 글루코실 레스베라트롤 50 mg/L에 비해 가용화도가 현저히 증가되었다. 또한, 스테비오사이드가 포함된 용액에 마이크로웨이브를 처리한 경우에는 가용화된 레스베라트롤의 양이 14,200 mg/L까지 향상됨을 확인하였으며, 이는 초기에 첨가해준 글루코실 레스베라트롤의 71.5% 가 가용화된 것이었다. In addition, the amount of finally solubilized glucosyl resveratrol in the sample added with 20% (w / v) stevioside was 8,500 mg / L, which was added to 50 mg / L solubilized glucosyl resveratrol in a solution containing no stevioside. Solubility was significantly increased in comparison. In addition, when microwave treatment of the solution containing steviosides was confirmed that the amount of solubilized resveratrol improved to 14,200 mg / L, which was 71.5% solubilization of the initially added glucosyl resveratrol.
상기 결과들로부터 스테비오사이드가 포함된 용액에 레스베라트롤 또는 글루코실 레스베라트롤을 녹이면, 스테비오사이드가 포함되지 않은 용액에 녹이 경우보다 이들의 가용화도가 현저히 증가되며, 더 나아가 레스베라트롤 또는 글루코실 레스베라트롤을 스테비오사이드가 포함된 용액에 녹인 후 마이크로웨이브를 처리해주면, 이들의 가용화도가 더 증가됨을 알 수 있었다.From the above results, when resveratrol or glucosyl resveratrol is dissolved in a solution containing steviosides, their solubility is significantly increased than when dissolved in a solution containing steviosides. After dissolving in the solution contained microwave treatment, it was found that their solubility is further increased.
동일한 방법으로 0, 10, 20% (w/v) 감초 추출물을 첨가하여 레스베라트롤 20 mg/ml의 농도로 녹이고, 70℃에서 초음파를 이용하여 15분간 처리하였다. 또한 마이크로웨이브를 이용하여 15분씩 2번 처리하여 각각의 용매로부터 가용화된 커큐민의 양을 HPLC를 이용하여 정량하였으며, 그 결과는 하기 표 7과 같았다.In the same manner, 0, 10, 20% (w / v) licorice extract was added to dissolve the resveratrol at a concentration of 20 mg / ml, and treated at 70 ° C. for 15 minutes using ultrasonic waves. In addition, the amount of curcumin solubilized from each solvent by treating twice with 15 minutes using a microwave was quantified by HPLC, and the results are shown in Table 7 below.
표 7
감초추출물 농도, % (w/v) 가용화된 레스베라트롤 (mg/L) 가용화된 글루코실 레스베라트롤 (mg/L)
초음파처리 마이크로웨이브 초음파처리 마이크로웨이브
0 10 100 50 530
10 5,400 7,700 5,400 14,200
20 8,600 11,600 10,500 17,300
TABLE 7
Licorice extract concentration,% (w / v) Solubilized Resveratrol (mg / L) Solubilized Glucosyl Resveratrol (mg / L)
Ultrasonic treatment Microwave Ultrasonic treatment Microwave
0 10 100 50 530
10 5,400 7,700 5,400 14,200
20 8,600 11,600 10,500 17,300
상기 표 7에서와 같이 감초 추출물을 20% (w/v) 첨가한 시료에서 최종적으로 가용화된 레스베라트롤의 양은 8,600 mg/L였으며, 이는 감초 추출물이 포함되지 않은 용액에서 가용화된 레스베라트롤 10 mg/L에 비해 가용화도가 현저히 증가됨을 확인할 수 있었다. 또한, 감초 추출물이 포함된 용액에 레스베라트롤을 녹인 후, 마이크로웨이브를 처리한 경우, 가용화된 레스베라트롤의 양이 11,600 mg/L까지 향상됨을 확인하였다. As shown in Table 7, the amount of resveratrol finally solubilized in the sample to which 20% (w / v) licorice extract was added was 8,600 mg / L, which was added to 10 mg / L solubilized resveratrol in a solution that did not contain licorice extract. It was confirmed that the solubility was significantly increased. In addition, after dissolving resveratrol in a solution containing licorice extract, when the microwave treatment, the amount of solubilized resveratrol was confirmed to improve to 11,600 mg / L.
또한, 감초 추출물을 20% (w/v) 첨가한 시료에서 최종적으로 가용화된 글루코실 레스베라트롤의 양은 10,500 mg/L 였으며, 이는 감초 추출물이 포함되지 않은 용액에서 가용화된 글루코실 레스베라트롤 50 mg/L에 비해 가용화도가 현저히 증가되었다. 또한, 감초 추출물이 포함된 용액에 마이크로웨이브를 처리한 경우에는 가용화된 레스베라트롤의 양이 17,300 mg/L까지 향상됨을 확인하였으며, 이는 초기에 첨가해준 글루코실 레스베라트롤의 86.5%가 가용화된 것이었다. In addition, the amount of finally solubilized glucosyl resveratrol in the sample to which 20% (w / v) licorice extract was added was 10,500 mg / L, which was added to 50 mg / L solubilized glucosyl resveratrol in a solution containing no licorice extract. Solubility was significantly increased in comparison. In addition, when microwave treatment of the solution containing licorice extract was confirmed that the amount of solubilized resveratrol improved to 17,300 mg / L, which was solubilized 86.5% of the initially added glucosyl resveratrol.
상기 결과들로부터 감초 추출물이 포함된 용액에 레스베라트롤 또는 글루코실 레스베라트롤을 녹이면, 감초 추출물이 포함되지 않은 용액에 녹인 경우보다 이들의 가용화도가 현저히 증가되며, 더 나아가 레스베라트롤 또는 글루코실 레스베라트롤을 감초 추출물이 포함된 용액에 녹인 후 마이크로웨이브를 처리해주면, 이들의 가용화도가 더 증가됨을 알 수 있었다.From the above results, when resveratrol or glucosyl resveratrol is dissolved in a solution containing licorice extract, their solubility is markedly increased than when dissolved in a solution that does not contain licorice extract. After dissolving in the solution contained microwave treatment, it was found that their solubility is further increased.
실시예 6: 스테비올 배당체와 감초추출물을 이용한 글리시리진산의 가용화Example 6: Solubilization of Glycyrrhizinic Acid Using Steviol Glycosides and Licorice Extract
시그마사로부터 구입한 글리시리진산을 5 mg/ml의 농도로 각각의 0.1-5% (w/v) 스테비오사이드 또는 감초 추출물 용액에 대하여 녹이고, 70℃에서 초음파를 이용하여 10분간 처리하였다. 또한 마이크로웨이브를 이용하여 15분씩 2번 처리하여 각각의 용매로부터 가용화된 글리시리진산의 양을 HPLC를 이용하여 정량하였다. The glycyrrhizinic acid purchased from Sigma was dissolved in each 0.1-5% (w / v) stevioside or licorice extract solution at a concentration of 5 mg / ml and treated for 10 minutes using ultrasonic waves at 70 ° C. In addition, the amount of glycyrrhizinic acid solubilized from each solvent by treating twice with 15 minutes using microwave was quantified using HPLC.
스테비오사이드를 0.1-0.5% (w/v) 첨가한 시료에서는 빠르게 겔화반응이 일어남을 확인하였다. 또한, 1-2% (w/v)의 스테비오사이드 첨가만으로도 초기에 첨가한 글리시리진산을 모두 가용화시키는데 성공하였다.It was confirmed that the gelation reaction occurred rapidly in the sample to which stevioside was added 0.1-0.5% (w / v). In addition, only 1-2% (w / v) stevioside addition succeeded in solubilizing all of the initially added glycyrrhizinic acid.
아울러, 이와 같은 방법으로 감초추출물을 이용한 결과 역시 0.1-0.5% (w/v)의 감초 추출물을 첨가하였을 때 겔화 반응이 보였고, 1% 이상의 감초 추출물의 첨가만으로 초기에 첨가한 글리시리진산을 모두 가용화시키는 것을 확인하였다.In addition, the result of using licorice extract in this manner also showed a gelation reaction when the licorice extract of 0.1-0.5% (w / v) was added, and all of the glycidyl acid initially added with only 1% or more licorice extract was solubilized. It was confirmed to make.
실시예 7: 스테비올 배당체와 감초추출물을 이용한 파클리탁솔의 가용화Example 7: Solubilization of Paclitaxol Using Steviol Glycosides and Licorice Extract
시그마사로부터 구입한 파클리탁솔을 10 mg/ml의 농도로 각각의 0, 5, 10, 20% (w/v) 스테비오사이드 또는 감초추출물 용액에 대하여 녹이고, 70℃에서 초음파를 이용하여 10분간 처리하고, 마이크로웨이브를 이용하여 15분씩 2번 처리하여 각각의 용매로부터 가용화된 커큐민의 양을 HPLC를 이용하여 정량하였다. Paclitaxol purchased from Sigma was dissolved in each of 0, 5, 10, 20% (w / v) stevioside or licorice extract solution at a concentration of 10 mg / ml, and 10 minutes using ultrasonic waves at 70 ° C. The amount of curcumin solubilized from each solvent was treated and treated twice with 15 minutes using microwaves to quantify using HPLC.
스테비오사이드를 10%, 20% (w/v) 농도로 첨가하고 초음파 처리하였을 때는 300 mg/L, 700 mg/L가 가용화 되었으나, 마이크로웨이브를 15분씩 두 번 처리하였을 때는 1,400 mg/L, 2,100 mg/L가 가용화됨을 확인할 수 있었다.When stevioside was added at a concentration of 10% and 20% (w / v) and sonicated, 300 mg / L and 700 mg / L were solubilized, but 1,400 mg / L and 2,100 when microwaved twice every 15 minutes. It could be seen that mg / L is solubilized.
감초추출물의 경우, 10%, 20% (w/v) 용액에서 스테비오사이드에 비해 가용화 정도가 미비하였으나, 20% (w/v) 용액에서 초음파 처리하였을 시에 800 mg/L, 그리고 마이크로웨이브를 처리하였을 때는 1,900 mg/L로 가용화가 향상됨을 알 수 있었다.For licorice extract, the solubilization was less than that of stevioside in 10% and 20% (w / v) solutions, but 800 mg / L and microwaves were sonicated when sonicated in 20% (w / v) solutions. It was found that solubilization was improved to 1,900 mg / L when treated.

Claims (27)

  1. 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초; 및 난용성 물질을 포함하는, 복합체.Steviol glycosides or stevia, or licorice comprising the same; And a poorly soluble material.
  2. 제1항에 있어서, 상기 스테비아 또는 감초는 이의 추출물 형태인 것인 복합체.The complex of claim 1, wherein the stevia or licorice is in the form of an extract thereof.
  3. 제1항에 있어서, 상기 복합체는 용매 내 스테비올 배당체, 스테비아, 또는 감초, 및 난용성 물질의 혼합물에 마이크로웨이브(microwave)를 처리하여 얻어진 제형인 것이 특징인 복합체.The complex according to claim 1, wherein the complex is a formulation obtained by treating microwaves with a mixture of steviol glycosides, stevia, or licorice in a solvent, and a poorly soluble substance.
  4. 제3항에 있어서, 상기 마이크로웨이브 처리는 작동중인 전자레인지에서 반응시키는 것이 특징인 복합체.4. The composite of claim 3 wherein said microwave treatment is reacted in a running microwave.
  5. 제3항에 있어서, 상기 마이크로웨이브 처리는 전자레인지에서 600 W 내지 800 W로 1분 내지 20분간 수행하는 것이 특징인 복합체.The composite according to claim 3, wherein the microwave treatment is performed for 1 to 20 minutes at 600 W to 800 W in a microwave oven.
  6. 제3항에 있어서, 상기 마이크로웨이브 처리는 전자레인지에서 140 W 내지 240 W로 1 분 내지 20분간 수행하는 것이 특징인 복합체.The composite according to claim 3, wherein the microwave treatment is performed for 1 to 20 minutes at 140 W to 240 W in a microwave oven.
  7. 제1항에 있어서, 상기 스테비올 배당체는 스테비오사이드(Stevioside), 효소처리 스테비오사이드, 레바우디오사이드(rebaudioside), 루부소사이드(rubusoside), 둘코사이드(dulcoside), 스테비올 비오사이드, 또는 스테비올 모노사이드인 것인 복합체.The method of claim 1, wherein the steviol glycosides are stevioside, enzymatically treated stevioside, rebaudioside, rubusoside, dulcoside, steviool bioside, or stevioside. The complex is a viol monoside.
  8. 제1항에 있어서, 상기 난용성 물질은 커큐미노이드계 화합물, 레스베라트롤(resveratrol), 글루코실 레스베라트롤, 글리실리진산(glycyrrhizinic acid), 또는 파클리탁셀(paclitaxel)인 것인 복합체.The complex of claim 1, wherein the poorly soluble substance is a curcuminoid compound, resveratrol, glucosyl resveratrol, glycyrrhizinic acid, or paclitaxel.
  9. 제1항에 있어서, 상기 스테비올 배당체는 1 내지 25%(w/v)의 농도로 포함되는 것이 특징인 복합체.The complex of claim 1, wherein the steviol glycoside is included at a concentration of 1 to 25% (w / v).
  10. 제1항에 있어서, 상기 감초는 0.1 내지 25%(w/v)의 농도로 포함되는 것이 특징이 복합체.The complex of claim 1, wherein the licorice is included at a concentration of 0.1 to 25% (w / v).
  11. 제1항 내지 제10항 중 어느 한 항의 복합체를 포함하는 약학 또는 식품 조성물.A pharmaceutical or food composition comprising the complex of any one of claims 1 to 10.
  12. 제1항 내지 제10항 중 어느 한 항의 복합체를 포함하는 화장료 조성물Cosmetic composition comprising the complex of any one of claims 1 to 10
  13. 제1항 내지 제10항 중 어느 한 항의 복합체를 포함하는 사료 조성물.Feed composition comprising a complex of any one of claims 1 to 10.
  14. 스테비올 배당체 또는 이를 포함하는 스테비아, 또는 감초, 및 난용성 물질을 혼합하는 제1단계; 및A first step of mixing a steviol glycoside or stevia or licorice comprising the same, and a poorly soluble substance; And
    상기 제1단계에서 얻어진 혼합물에 마이크로웨이브(microwave)를 처리하는 제2단계를 포함하는, 가용성이 증가된 난용성 물질 함유 복합체의 제조방법.And a second step of subjecting the mixture obtained in the first step to microwave (microwave).
  15. 제14항에 있어서, 상기 제1단계는 용매에서 혼합하거나, 또는 스테비올 배당체 또는 스테비아, 또는 감초가 포함된 용액에 난용성 물질을 첨가하는 것이 특징인 방법.The method of claim 14, wherein the first step is mixing in a solvent or adding a poorly soluble substance to a solution containing steviol glycosides or stevia or licorice.
  16. 제14항에 있어서, 상기 제2단계는 전자레인지에서 600 W 내지 800 W로 1분 내지 20분간 마이크로웨이브를 처리하는 것이 특징인 방법.15. The method of claim 14, wherein the second step is to treat the microwave for 1 to 20 minutes at 600 W to 800 W in a microwave oven.
  17. 제14항에 있어서, 상기 제2단계는 전자레인지에서 140 W 내지 240 W로 1 분 내지 20분간 마이크로웨이브를 처리하는 것이 특징인 방법.15. The method of claim 14, wherein the second step is to treat the microwave at 140 W to 240 W for 1 to 20 minutes in a microwave oven.
  18. 제14항에 있어서, 상기 스테비올 배당체는 스테비오사이드, 효소처리 스테비오사이드, 레바우디오사이드(rebaudioside), 루부소사이드(rubusoside), 스테비올 비오사이드, 또는 스테비올 모노사이드인 것이 특징인 방법.The method of claim 14, wherein the steviol glycoside is stevioside, enzymatically treated stevioside, rebaudioside, rubusoside, steviool bioside, or steviol monoside.
  19. 제14항에 있어서, 상기 난용성 물질은 커큐미노이드계 화합물, 레스베라트롤(resveratrol), 글루코실 레스베라트롤, 글리실리진산(glycyrrhizinic acid), 또는 파클리탁셀(paclitaxel)인 것이 특징인 방법.The method of claim 14, wherein the poorly soluble substance is a curcuminoid compound, resveratrol, glucosyl resveratrol, glycyrrhizinic acid, or paclitaxel.
  20. 제14항에 있어서, 상기 제1단계에서 스테비올 배당체는 1 내지 25%(w/v)의 농도로 포함되는 것이 특징인 방법.The method of claim 14, wherein the steviol glycosides in the first step are included at a concentration of 1 to 25% (w / v).
  21. 제14항에 있어서, 상기 제1단계에서 감초는 0.1 내지 25%(w/v)의 농도로 포함되는 것이 특징인 방법.The method of claim 14, wherein the licorice in the first step is characterized in that it comprises a concentration of 0.1 to 25% (w / v).
  22. 제 14항에 있어서, 상기 제1단계는 60℃ 내지 80℃에서 수행하는 것이 특징인 방법.The method of claim 14, wherein the first step is performed at 60 ° C to 80 ° C.
  23. 제14항에 있어서, 상기 제2단계 이전에 제1단계의 결과물을 초음파 처리 하는 단계를 더 포함하는 것을 특징으로 하는 방법.15. The method of claim 14, further comprising the step of sonicating the resultant of the first step prior to the second step.
  24. 감초를 유효성분으로 함유하는 가용화제.Solubilizer containing licorice as an active ingredient.
  25. 제24항에 있어서, 상기 감초는 감초 추출물의 형태인 것인 가용화제.The solubilizer of claim 24 wherein the licorice is in the form of a licorice extract.
  26. 감초와 난용성 물질을 혼합하는 단계를 포함하는, 난용성 물질을 가용화시키는 방법.A method of solubilizing poorly soluble material, comprising mixing licorice with poorly soluble material.
  27. 가용화제의 제조에 있어서, 감초의 용도.Use of licorice in the preparation of solubilizers.
PCT/KR2012/006069 2011-07-29 2012-07-30 Complex comprising steviol glycosides orlicorice root, and poorly soluble material WO2013019049A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0076212 2011-07-29
KR20110076212 2011-07-29

Publications (1)

Publication Number Publication Date
WO2013019049A1 true WO2013019049A1 (en) 2013-02-07

Family

ID=47629488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006069 WO2013019049A1 (en) 2011-07-29 2012-07-30 Complex comprising steviol glycosides orlicorice root, and poorly soluble material

Country Status (2)

Country Link
KR (1) KR101436464B1 (en)
WO (1) WO2013019049A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101924159B1 (en) 2016-04-15 2018-11-30 서울대학교산학협력단 Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same
US10456343B2 (en) 2017-01-26 2019-10-29 L'oreal Microemulsion compositions comprising polydatin and method of use
CN111388676A (en) * 2020-02-11 2020-07-10 湖南中茂生物科技有限公司 Composition for improving water solubility of curcumin and application of composition in preparation of compound for treating senile dementia

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150086928A (en) * 2014-01-21 2015-07-29 한국생명공학연구원 Composition for prevention or treatment of influenza virus infection comprising curcuminoid and licorice extracts or fraction thereof
WO2016143939A1 (en) * 2015-03-09 2016-09-15 서울대학교산학협력단 Production method for complex of steviol glycoside and sparingly soluble material having improved solubility, and complex of steviol glycoside and sparingly soluble material having improved solubility produced thereby
KR101719579B1 (en) * 2015-03-09 2017-03-24 서울대학교산학협력단 Manufacturing method of insoluble materials steviolglycosides composite for improving solubility of insoluble materials and insoluble materials steviolglycosides composite made by the same
KR102662257B1 (en) * 2016-10-26 2024-05-02 주식회사 엘지생활건강 Composition for skin improvement containing rebaudioside C
KR102613550B1 (en) * 2018-05-17 2023-12-14 한국생명공학연구원 A ginsenoside complex comprising insoluble substance curcumin
KR20200071028A (en) * 2018-12-10 2020-06-18 서울대학교산학협력단 Solubilizing composition of insoluble material comprising ligosaccharides prepared using lactic acid bacteria
WO2022220521A1 (en) * 2021-04-12 2022-10-20 표상현 Amphipathic compound, preparation method therefor, and surfactant composition comprising same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001103932A (en) * 1999-10-12 2001-04-17 Higashimaru Shoyu Co Ltd Solubilized preparation of oil-extract of licorice
JP2004065128A (en) * 2002-08-07 2004-03-04 Maruzen Pharmaceut Co Ltd Solubilizing composition for licorice oily extract, and beverage, liquid seasoning, cosmetic and quasi-drug
JP2005168458A (en) * 2003-12-15 2005-06-30 Toyo Seito Kk Water-soluble food and beverage and production method therefor
JP2011051938A (en) * 2009-09-02 2011-03-17 Toyo Seito Kk Highly absorbable drug composition and method for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758122C (en) * 2008-04-11 2017-05-16 Zhijun Liu Diterpene glycosides as natural solubilizers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001103932A (en) * 1999-10-12 2001-04-17 Higashimaru Shoyu Co Ltd Solubilized preparation of oil-extract of licorice
JP2004065128A (en) * 2002-08-07 2004-03-04 Maruzen Pharmaceut Co Ltd Solubilizing composition for licorice oily extract, and beverage, liquid seasoning, cosmetic and quasi-drug
JP2005168458A (en) * 2003-12-15 2005-06-30 Toyo Seito Kk Water-soluble food and beverage and production method therefor
JP2011051938A (en) * 2009-09-02 2011-03-17 Toyo Seito Kk Highly absorbable drug composition and method for producing the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101924159B1 (en) 2016-04-15 2018-11-30 서울대학교산학협력단 Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same
US10456343B2 (en) 2017-01-26 2019-10-29 L'oreal Microemulsion compositions comprising polydatin and method of use
CN111388676A (en) * 2020-02-11 2020-07-10 湖南中茂生物科技有限公司 Composition for improving water solubility of curcumin and application of composition in preparation of compound for treating senile dementia

Also Published As

Publication number Publication date
KR101436464B1 (en) 2014-09-01
KR20130014451A (en) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2013019049A1 (en) Complex comprising steviol glycosides orlicorice root, and poorly soluble material
WO2020235928A1 (en) Anti-influenza virus composition, composition for treating respiratory diseases, and anti-aging composition, comprising dark ginseng extract
WO2017095138A1 (en) Curcumin-containing lipid nanoparticle complex comprising ginsenosides
WO2018174448A1 (en) Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same
WO2020218720A1 (en) Composition for preventing or treating muscular disorders or improving muscular functions, containing leonurus japonicus extract or leonurine
WO2014204104A1 (en) Method of producing compound having decreased sugar from glycoside, extract, and pharmaceutical and food compositions including the compound
WO2016010340A1 (en) Composition for preventing and treating inflammation or allergic diseases, containing gynura procumbens extract as active ingredient, and use thereof
WO2018139809A1 (en) Composition containing, as active ingredient, ginseng flower extract having increased amount of ginsenosides
WO2021080297A1 (en) Composition containing evening primrose flower extract as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2017146486A1 (en) Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract
WO2011099812A2 (en) Composition for preventing or treating rotavirus infection containing licorice extract
WO2013012117A1 (en) Pharmaceutical compositions for preventing or treating inflammatory diseases, comprising phytosterol compound
WO2013069934A1 (en) Composition for treating and preventing obesity, containing wheatgrass extract as active ingredient
WO2018221922A1 (en) Composition for preventing and treating muscle-related diseases, containing coptidis rhizoma extract, and use thereof
WO2009151236A2 (en) The composition comprising extracts or fractions of magnolia obovata thunb for treating and preventing inflammation disease
WO2021002642A1 (en) Composition for preventing or treating rheumatoid arthritis, comprising snake venom
WO2021246833A1 (en) Composition, for preventing or treating inflammatory disease, comprising hydrolysis extract of pulsatilla koreana and anemone raddeana as active ingredient
WO2020130478A1 (en) Anti-allergy, atopic dermatitis alleviation or skin regeneration composition containing jasmone as active ingredient
WO2019245245A1 (en) Pharmaceutical composition for preventing and treating liver damage comprising turmeric extract
WO2015105373A1 (en) Composition for prevention or treatment of asthma, comprising e uonymus alatus extract or fraction thereof
WO2018190638A1 (en) Composition for preventing or treating corneal diseases, containing glycine max extract
WO2015111904A1 (en) Composition for preventing or treating influenza virus infection comprising curcuminoid-based compound and licorice extract or fraction thereof
WO2020218840A1 (en) Composition for inhibiting hair loss or promoting hair growth containing plant extract removed of chlorophyll or pigment as active ingredient, and method for producing same
WO2013022178A1 (en) Composition for the prevention and treatment of obesity containing an active ingredient in the form of a fermented or unfermented lonicera japonica and aurantii nobilis pericarpium mixed herbal-preparation extract, and a use therefor
WO2022270760A1 (en) Method for treating non-alcoholic steatohepatitis through co-administration of curcumin derivative and tgf-β receptor inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819554

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12819554

Country of ref document: EP

Kind code of ref document: A1